<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PREVACID - lansoprazole capsule, delayed release </strong><br><strong>PREVACID - lansoprazole tablet, orally disintegrating, delayed release </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Italics">These highlights do not include all the information needed to use PREVACID safely and effectively.  See full prescribing information for:</span><br>PREVACID (lansoprazole) Delayed-Release Capsules<br>PREVACID SoluTab (lansoprazole) Delayed-Release Orally Disintegrating Tablets <br> <br>For oral administration<br>Initial U.S. Approval: 1995</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">WARNINGS AND PRECAUTIONS </p>
<a name="i23371a98-e2e6-498f-8f2d-95bc71a34ebb"></a><table width="75%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr class="First Last Toprule">
<td align="left"><ul>
<li>Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span> (<a href="#S5.2">5.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span> (<a href="#S5.3">5.3</a>)</li>
</ul></td>
<td align="left">9/2010<br>5/2011</td>
</tr></tbody>
</table>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">PREVACID is a proton pump inhibitor (PPI). Refer to DOSAGE and ADMINISTRATION table (below) for indications and usage.   (<a href="#section-1">1</a>)</p></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<a name="table"></a><table width="80%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="30%">
<col align="left" valign="middle" width="10%">
<col align="left" valign="middle" width="40%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left" colspan="2">Indication</th>
<th class="Rrule" align="left">Dose</th>
<th class="Rrule" align="left">Frequency</th>
</tr></thead>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="4">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcers</span> </span>(<a href="#S1.1">1.1</a>, <a href="#S1.3">1.3</a>)</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2">Short-Term Treatment</td>
<td class="Rrule" align="left">15 mg</td>
<td class="Rrule" align="left">Once daily for 4 wks</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2">Maintenance of Healed</td>
<td class="Rrule" align="left">15 mg</td>
<td class="Rrule" align="left">Once daily</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4">
<span class="Bold Italics"> H. pylori</span><span class="Bold"> Eradication to Reduce Recurrence of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> </span>(<a href="#S1.2">1.2</a>)</td></tr>
<tr class="Botrule">
<td class="Lrule" align="left">Triple Therapy: </td>
<td class="Rrule" align="left">PREVACID<br>Amoxicillin<br>Clarithromycin</td>
<td class="Rrule" align="left">30 mg<br>1 gram<br>500 mg</td>
<td class="Rrule" align="left">Twice daily for 10 or 14 days</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Dual Therapy: </td>
<td class="Rrule" align="left">PREVACID<br>Amoxicillin</td>
<td class="Rrule" align="left">30 mg<br>1 gram</td>
<td class="Rrule" align="left">Three times daily for 14 days</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2">
<span class="Bold">Benign <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span> Short-Term Treatment </span>(<a href="#S1.4">1.4</a>)</td>
<td class="Rrule" align="left">30 mg</td>
<td class="Rrule" align="left">Once daily up to 8 wks</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4">
<span class="Bold">NSAID-associated <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span> </span>(<a href="#S1.6">1.6</a>)</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2">Healing<br>Risk Reduction </td>
<td class="Rrule" align="left">30 mg<br>15 mg</td>
<td class="Rrule" align="left">Once daily for 8 wks<br>Once daily up to 12 wks</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> </span>(<a href="#S1.7">1.7</a>)</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2">Short-Term Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span></td>
<td class="Rrule" align="left">15 mg</td>
<td class="Rrule" align="left">Once daily up to 8 wks</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2">Short-Term Treatment of EE</td>
<td class="Rrule" align="left">30 mg</td>
<td class="Rrule" align="left">Once daily up to 8 wks</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2">
<span class="Bold">Pediatric </span>(<a href="#S8.4">8.4</a>)</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4">(1 to 11 years of age) Short-Term Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> and Short-Term Treatment of EE</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2">  ≤ 30 kg</td>
<td class="Rrule" align="left">15 mg</td>
<td class="Rrule" align="left">Once daily up to 12 wks</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2">  &gt; 30 kg</td>
<td class="Rrule" align="left">30 mg</td>
<td class="Rrule" align="left">Once daily up to 12 wks</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4">(12 to 17 years of age) Short-Term Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2">Nonerosive <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span></td>
<td class="Rrule" align="left">15 mg</td>
<td class="Rrule" align="left">Once daily up to 8 wks</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2">EE</td>
<td class="Rrule" align="left">30 mg</td>
<td class="Rrule" align="left">Once daily up to 8 wks</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2">
<span class="Bold">Maintenance of Healing of EE </span>(<a href="#S1.8">1.8</a>)</td>
<td class="Rrule" align="left">15 mg</td>
<td class="Rrule" align="left">Once daily</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" colspan="2">
<span class="Bold">Pathological Hypersecretory Conditions (i.e., ZES) </span>(<a href="#S1.9">1.9</a>)</td>
<td class="Rrule" align="left">60 mg</td>
<td class="Rrule" align="left">Once daily</td>
</tr>
</tbody>
</table>
</div>
<div></div>
<div></div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Capsules and Tablets: 15 mg and 30 mg. (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Contraindicated in patients with known severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of the PREVACID formulation. (<a href="#S4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<ul>
<li>Symptomatic response with PREVACID does not preclude the presence of gastric 
malignancy. (<a href="#S5.1">5.1</a>)</li>
<li>Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span>: Long-term and multiple daily dose PPI therapy may be 
associated with an increased risk for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of the hip, 
wrist or spine. (<a href="#S5.2">5.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span> has been reported rarely with prolonged treatment with PPIs. 
(<a href="#S5.3">5.3</a>)</li>
</ul>
<p class="Highlighta"> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most commonly reported adverse reactions (≥1%): <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. (<a href="#S6">6</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals America Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Do not co-administer with atazanavir. (<a href="#S7">7</a>)</li>
<li>May interfere with the absorption of drugs where gastric pH is important for bioavailability. (<a href="#S7">7</a>)</li>
<li>Concomitant warfarin use may require monitoring for increases in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. (<a href="#S7">7</a>)</li>
<li>Concomitant tacrolimus use may increase tacrolimus whole blood concentrations. (<a href="#S7">7</a>)</li>
<li>Titration of theophylline dosage may be required when concomitant PREVACID use is started or stopped. (<a href="#S7">7</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Consider dose adjustment in patients with severe liver impairment. (<a href="#S8.7">8.7</a>) </p></div>
<div><div><div></div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div><div></div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div><div><div></div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 6/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	Short-Term Treatment of Active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> </a></h2>
<h2><a href="#section-1.2" class="toc">1.2	<span class="Italics">H. pylori</span> Eradication to Reduce the Risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Recurrence</a></h2>
<h2><a href="#section-1.3" class="toc">1.3	Maintenance of Healed <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcers</span></a></h2>
<h2><a href="#section-1.4" class="toc">1.4	Short-Term Treatment of Active Benign <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span></a></h2>
<h2><a href="#section-1.5" class="toc">1.5	Healing of NSAID-Associated <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span></a></h2>
<h2><a href="#section-1.6" class="toc">1.6	Risk Reduction of NSAID-Associated <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span></a></h2>
<h2><a href="#section-1.7" class="toc">1.7	<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>)</a></h2>
<h2><a href="#section-1.8" class="toc">1.8	Maintenance of Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> (EE)</a></h2>
<h2><a href="#section-1.9" class="toc">1.9	Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome (ZES)</a></h2>
<h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Recommended Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Special Populations</a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Important Administration Information</a></h2>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">Gastric Malignancy</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></a></h2>
<h1><a href="#section-6" class="toc">6	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience</a></h2>
<h2><a href="#section-6.3" class="toc">6.3	Combination Therapy with Amoxicillin and Clarithromycin</a></h2>
<h2><a href="#section-6.4" class="toc">6.4	Laboratory Values</a></h2>
<h1><a href="#section-7" class="toc">7	DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5	Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8	Gender</a></h2>
<h2><a href="#section-8.8" class="toc">8.9	Race</a></h2>
<h1><a href="#section-9" class="toc">10	OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11	DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2	Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3	Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc">12.4	Specific Populations</a></h2>
<h2><a href="#section-11.5" class="toc">12.5	Drug-Drug Interactions</a></h2>
<h1><a href="#section-12" class="toc">13	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2	Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14	CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">15	REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17	PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1	Information for Patients</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1	Short-Term Treatment of Active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> </h2>
<p class="First">PREVACID<span class="Sup">®</span> is indicated for short-term treatment (for 4 weeks) for healing and symptom relief of active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2	<span class="Italics">H. pylori</span> Eradication to Reduce the Risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Recurrence</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2.1"></a><p></p>
<p class="First"><span class="Italics">Triple Therapy:  PREVACID/amoxicillin/clarithromycin</span></p>
<p>PREVACID in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with<span class="Italics"> H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease (active or one-year history of a <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>) to eradicate <span class="Italics">H. pylori.</span> Eradication of <span class="Italics">H. pylori</span> has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> recurrence <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. 										</p>
<p>Please refer to the full prescribing information for amoxicillin and clarithromycin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2.2"></a><p></p>
<p class="First"><span class="Italics">Dual Therapy:  PREVACID/amoxicillin</span></p>
<p>PREVACID in combination with amoxicillin as dual therapy is indicated for the treatment of patients with <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease (active or one-year history of a <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>) <span class="Bold">who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected</span> (see the clarithromycin package insert, MICROBIOLOGY section). Eradication of <span class="Italics">H. pylori</span> has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> recurrence <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. 										</p>
<p>Please refer to the full prescribing information for amoxicillin.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3	Maintenance of Healed <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcers</span></h2>
<p class="First">PREVACID is indicated to maintain healing of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>. Controlled studies do not extend beyond 12 months <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.4"></a><a name="section-1.4"></a><p></p>
<h2>1.4	Short-Term Treatment of Active Benign <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span></h2>
<p class="First">PREVACID is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of active benign <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span> <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.5"></a><a name="section-1.5"></a><p></p>
<h2>1.5	Healing of NSAID-Associated <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span></h2>
<p class="First">PREVACID is indicated for the treatment of NSAID-associated <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span> in patients who continue NSAID use. Controlled studies did not extend beyond 8 weeks <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.6"></a><a name="section-1.6"></a><p></p>
<h2>1.6	Risk Reduction of NSAID-Associated <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span></h2>
<p class="First">PREVACID is indicated for reducing the risk of NSAID-associated <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span> in patients with a history of a documented <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span> who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.7"></a><a name="section-1.7"></a><p></p>
<h2>1.7	<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>)</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.7.1"></a><p></p>
<p class="First"><span class="Italics">Short-Term Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span></span></p>
<p>PREVACID is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> and other symptoms associated with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. 										</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.7.2"></a><p></p>
<p class="First"><span class="Italics">Short-Term Treatment of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></span></p>
<p>PREVACID is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of all grades of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>. </p>
<p>For patients who do not heal with PREVACID for 8 weeks (5 to 10%), it may be helpful to give an additional 8 weeks of treatment.  If there is a recurrence of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> an additional 8-week course of PREVACID may be considered <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. 										</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.8"></a><a name="section-1.8"></a><p></p>
<h2>1.8	Maintenance of Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> (EE)</h2>
<p class="First">PREVACID is indicated to maintain healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>. Controlled studies did not extend beyond 12 months <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.9"></a><a name="section-1.9"></a><p></p>
<h2>1.9	Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome (ZES)</h2>
<p class="First">PREVACID is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. 								</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2	DOSAGE AND ADMINISTRATION</h1>
<p class="First">PREVACID is available as a capsule and an orally disintegrating tablet, and is available in 15 mg and 30 mg strengths. Directions for use specific to the route and available methods of administration for each of these dosage forms is presented below. PREVACID should be taken before eating. PREVACID products SHOULD NOT BE CRUSHED OR CHEWED.  In the clinical trials, antacids were used concomitantly with PREVACID.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Recommended Dose</h2>
<a name="ibd77622c-0d17-48ae-86a0-b1493aaac857"></a><table width="100%">
<col align="left" valign="top" width="40%">
<col align="left" valign="middle" width="20%">
<col align="left" valign="middle" width="40%">
<thead><tr class="First Last">
<th align="left" valign="bottom">Indication</th>
<th align="left" valign="bottom">Recommended Dose</th>
<th align="left" valign="bottom">Frequency</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Please refer to amoxicillin and clarithromycin full prescribing information for CONTRAINDICATIONS and WARNINGS, and for information regarding dosing in elderly and renally-impaired patients.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Controlled studies did not extend beyond indicated duration.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>For patients who do not heal with PREVACID for 8 weeks (5 to 10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>, an additional 8 week course of PREVACID may be considered.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>The PREVACID dose was increased (up to 30 mg twice daily) in some pediatric patients after 2 or more weeks of treatment if they remained symptomatic. For pediatric patients unable to swallow an intact capsule please see <a href="#Administration">Administration Options</a>.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">¶</a></dt>
<dd>Varies with individual patient. Recommended adult starting dose is 60 mg once daily. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Dosages up to 90 mg twice daily have been administered. Daily dose of greater than 120 mg should be administered in divided doses. Some patients with Zollinger-Ellison Syndrome have been treated continuously with PREVACID for more than 4 years.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left"><span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcers</span></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">  Short-Term Treatment</td>
<td align="left">15 mg</td>
<td align="left">Once daily for 4 weeks</td>
</tr>
<tr class="Botrule">
<td align="left">  Maintenance of Healed</td>
<td align="left">15 mg</td>
<td align="left">Once daily</td>
</tr>
<tr>
<td align="left">
<span class="Italics">H. pylori</span> Eradication to Reduce the Risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Recurrence<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">  Triple Therapy:</td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">    PREVACID</td>
<td align="left">30 mg</td>
<td align="left">Twice daily (q12h) for 10 or 14 days</td>
</tr>
<tr>
<td align="left">    Amoxicillin</td>
<td align="left">1 gram</td>
<td align="left">Twice daily (q12h) for 10 or 14 days</td>
</tr>
<tr>
<td align="left">    Clarithromycin</td>
<td align="left">500 mg</td>
<td align="left">Twice daily (q12h) for 10 or 14 days</td>
</tr>
<tr>
<td align="left">  Dual Therapy:</td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">    PREVACID</td>
<td align="left">30 mg</td>
<td align="left">Three times daily (q8h) for 14 days</td>
</tr>
<tr class="Botrule">
<td align="left">    Amoxicillin</td>
<td align="left">1 gram</td>
<td align="left">Three times daily (q8h) for 14 days</td>
</tr>
<tr>
<td align="left">Benign <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr class="Botrule">
<td align="left">  Short-Term Treatment</td>
<td align="left">30 mg</td>
<td align="left">Once daily for up to 8 weeks</td>
</tr>
<tr>
<td align="left">NSAID-associated <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">  Healing</td>
<td align="left">30 mg</td>
<td align="left">Once daily for 8 weeks<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
</tr>
<tr class="Botrule">
<td align="left">  Risk Reduction </td>
<td align="left">15 mg</td>
<td align="left">Once daily for up to 12 weeks<a href="#footnote-2" class="Sup">†</a>
</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>)</td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">  Short-Term Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span></td>
<td align="left">15 mg</td>
<td align="left">Once daily for up to 8 weeks</td>
</tr>
<tr class="Botrule">
<td align="left">  Short-Term Treatment of  <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></td>
<td align="left">30 mg</td>
<td align="left">Once daily for up to 8 weeks<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
</tr>
<tr>
<td align="left">Pediatric</td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr><td align="left" colspan="3">(1 to 11 years of age)<br>Short-Term Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> and Short-Term Treatment of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></td></tr>
<tr>
<td align="left">  ≤ 30 kg</td>
<td align="left">15 mg</td>
<td align="left">Once daily for up to 12 weeks<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
</tr>
<tr>
<td align="left">  &gt; 30 kg</td>
<td align="left">30 mg</td>
<td align="left">Once daily for up to 12 weeks<a href="#footnote-4" class="Sup">§</a>
</td>
</tr>
<tr><td align="left" colspan="3">(12 to 17 years of age)<br>Short-Term Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span></td></tr>
<tr>
<td align="left">  Nonerosive <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span></td>
<td align="left">15 mg</td>
<td align="left">Once daily for up to 8 weeks</td>
</tr>
<tr class="Botrule">
<td align="left">  <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></td>
<td align="left">30 mg</td>
<td align="left">Once daily for up to 8 weeks</td>
</tr>
<tr>
<td align="left">Maintenance of Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></td>
<td align="left">15 mg</td>
<td align="left">Once daily</td>
</tr>
<tr class="Last">
<td align="left">Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome</td>
<td align="left">60 mg</td>
<td align="left">Once daily<a name="footnote-reference-5" href="#footnote-5" class="Sup">¶</a>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Special Populations</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> patients and geriatric patients do not require dosage adjustment. However, consider dose adjustment in patients with severe liver impairment <span class="Italics">[see <a href="#S8.5">Use in Specific Populations (8.5,</a><a href="#S8.6"> 8.6</a> and <a href="#S8.7">8.7</a>)]</span>. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Important Administration Information</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Administration"></a><a name="section-2.3.1"></a><p></p>
<p class="First"><span class="Italics">Administration Options </span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.1.1"></a><p></p>
<p class="First"><span class="Italics">PREVACID Delayed-Release Capsules - Oral Administration</span></p>
<ul class="Disc">
<li>PREVACID Delayed-Release Capsules should be swallowed whole.</li>
<li>Alternatively, for patients who have difficulty swallowing capsules, PREVACID Delayed-Release Capsules can be opened and administered as follows: 							<ul class="Circle">
<li>Open capsule.</li>
<li>Sprinkle intact granules on one tablespoon of either applesauce, ENSURE<span class="Sup">®</span> pudding, cottage cheese, yogurt or strained pears.</li>
<li>Swallow immediately.</li>
</ul>
</li>
<li>PREVACID Delayed-Release Capsules may also be emptied into a small volume of either apple juice, orange juice or tomato juice and administered as follows: 							<ul class="Circle">
<li>Open capsule.</li>
<li>Sprinkle intact granules into a small volume of either apple juice, orange juice or tomato juice (60 mL – approximately 2 ounces).</li>
<li>Mix briefly.</li>
<li>Swallow immediately.</li>
<li>To ensure complete delivery of the dose, the glass should be rinsed with two or more volumes of juice and the contents swallowed immediately.</li>
</ul>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.1.2"></a><p></p>
<p class="First"><span class="Italics">PREVACID Delayed-Release Capsules - Nasogastric Tube (≥16 French) Administration</span></p>
<ul><li>For patients who have a nasogastric tube in place, PREVACID Delayed-Release Capsules can be administered as follows: 													<ul>
<li>Open capsule.</li>
<li>Mix intact granules into 40 mL of apple juice. DO NOT USE OTHER LIQUIDS.</li>
<li>Inject through the nasogastric tube into the stomach. </li>
<li>Flush with additional apple juice to clear the tube. </li>
</ul>
</li></ul>
<p>USE IN OTHER FOODS AND LIQUIDS HAS NOT BEEN STUDIED CLINICALLY AND IS THEREFORE NOT RECOMMENDED.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.1.3"></a><p></p>
<p class="First"><span class="Italics">PREVACID SoluTab</span>™<span class="Italics"> Delayed-Release Orally Disintegrating Tablets</span></p>
<ul>
<li>PREVACID SoluTab should not be broken or cut.</li>
<li>PREVACID SoluTab should not be chewed. 													<ul class="Circle">
<li>Place the tablet on the tongue and allow it to disintegrate, with or without water, until the particles can be swallowed.</li>
<li>The tablet typically disintegrates in less than 1 minute.</li>
<li>Alternatively, for children or other patients who have difficulty swallowing tablets, PREVACID SoluTab can be delivered in two different ways. 	<br><span class="Italics">PREVACID SoluTab – Oral Syringe</span><br>For administration via oral syringe, PREVACID SoluTab can be administered as follows: <br><ul class="Square">
<li>Place a 15 mg tablet in oral syringe and draw up approximately 4 mL of water, or place a 30 mg tablet in oral syringe and draw up approximately 10 mL of water.</li>
<li>Shake gently to allow for a quick dispersal.</li>
<li>After the tablet has dispersed, administer the contents within 15 minutes.</li>
<li>Refill the syringe with approximately 2 mL (5 mL for the 30 mg tablet) of water, shake gently, and administer any remaining contents.</li>
</ul>
<br><span class="Italics">PREVACID SoluTab – Nasogastric Tube (≥ 8 French) Administration</span><br>																		For administration via a nasogastric tube, PREVACID SoluTab can be administered as follows: 																		<ul class="Square">
<li>Place a 15 mg tablet in a syringe and draw up 4 mL of water, or place a 30 mg tablet in a syringe and draw up 10 mL of water.</li>
<li>Shake gently to allow for a quick dispersal.</li>
<li>After the tablet has dispersed, inject through the nasogastric tube into the stomach within 15 minutes.</li>
<li>Refill the syringe with approximately 5 mL of water, shake gently, and flush the nasogastric tube.</li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<ul>
<li>15 mg capsules are opaque, hard gelatin, colored pink and green with the TAP logo and "PREVACID 15" imprinted on the capsule.</li>
<li>30 mg capsules are opaque, hard gelatin, colored pink and black with the TAP logo and "PREVACID 30" imprinted on the capsule.</li>
<li> </li>
<li>15 mg tablets are white to yellowish white, uncoated, colored orange to dark brown speckles with "15" debossed on one side of the tablet.</li>
<li>30 mg tablets are white to yellowish white, uncoated, colored orange to dark brown speckles with "30" debossed on one side of the tablet.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS</h1>
<p class="First">							PREVACID is contraindicated in patients with known severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of the formulation of PREVACID. 						</p>
<p>						For information on contraindications for amoxicillin or clarithromycin, refer to their full prescribing information, CONTRAINDICATIONS sections. 						</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<br><div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">Gastric Malignancy</span></h2>
<p class="First"></p>
<p>Symptomatic response to therapy with lansoprazole does not 
preclude the presence of <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">gastric malignancy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>5.2 Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></h2>
<p class="First"></p>
<p><span>Several 
published observational studies suggest that proton pump inhibitor (PPI) therapy 
may be associated with an increased risk for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of 
the hip, wrist or spine. The risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> was increased in patients who 
received high-dose, defined as multiple daily doses, and long-term PPI therapy 
(a year or longer). Patients should use the lowest dose and shortest duration of 
PPI therapy appropriate to the condition being treated. Patients at risk for 
<span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> should be managed according to established 
treatment guidelines <span class="Italics">[see <a href="#S2">Dosage and 
Administration (2)</a> and <a href="#S6">Adverse Reactions 
(6.2)</a>]</span>.</span></p>
<p>For information on warnings and precautions for amoxicillin or 
clarithromycin, refer to their full prescribing information, WARNINGS and 
PRECAUTIONS sections.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></h2>
<p class="First"></p>
<p><span><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span>, 
symptomatic and asymptomatic, has been reported rarely in patients treated with 
PPIs for at least three months, in most cases after a year of therapy. Serious 
adverse events include <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. In most patients, 
treatment of <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> required magnesium replacement and discontinuation 
of the PPI.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"> </span><span>For 
patients expected to be on prolonged treatment or who take PPIs with medications 
such as digoxin or drugs that may cause <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> (e.g., diuretics), health 
care professionals may consider monitoring magnesium levels prior to initiation 
of PPI treatment and periodically <span class="Italics">[see <a href="#S6.2">Adverse Reactions (6.2)</a>].</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6	ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical</h2>
<p class="First">Worldwide, over 10,000 patients have been treated with PREVACID in Phase 2 or Phase 3 clinical trials involving various dosages and durations of treatment. In general, PREVACID treatment has been well-tolerated in both short-term and long-term trials.</p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The following adverse reactions were reported by the treating physician to have a possible or probable relationship to drug in 1% or more of PREVACID-treated patients and occurred at a greater rate in PREVACID-treated patients than placebo-treated patients in Table 1.</p>
<a name="table1"></a><table width="80%">
<caption><span>Table 1: Incidence of Possibly or Probably Treatment-Related Adverse Reactions in Short-Term, Placebo-Controlled PREVACID Studies</span></caption>
<col align="left" valign="middle" width="34%">
<col align="center" valign="middle" width="33%">
<col align="center" valign="middle" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Body System/Adverse Event</th>
<th class="Rrule" align="center">PREVACID<br>(N= 2768)<br>%</th>
<th class="Rrule" align="center">Placebo<br>(N= 1023)<br>%</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">Body as a Whole</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Rrule" align="center">2.1</td>
<td class="Rrule" align="center">1.2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Digestive System</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">1.0</td>
<td class="Rrule" align="center">0.4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">3.8</td>
<td class="Rrule" align="center">2.3</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">1.3</td>
<td class="Rrule" align="center">1.2</td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> was also seen at greater than 1% incidence but was more common on placebo. The incidence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was similar between patients who received placebo and patients who received 15 mg and 30 mg of PREVACID, but higher in the patients who received 60 mg of PREVACID (2.9%, 1.4%, 4.2%, and 7.4%, respectively).</p>
<p>The most commonly reported possibly or probably treatment-related adverse event during maintenance therapy was <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p>In the risk reduction study of PREVACID for NSAID-associated <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span>, the incidence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> for patients treated with PREVACID, misoprostol, and placebo was 5%, 22%, and 3%, respectively.</p>
<p>Another study for the same indication, where patients took either a COX-2 inhibitor or lansoprazole and naproxen, demonstrated that the safety profile was similar to the prior study. Additional reactions from this study not previously observed in other clinical trials with PREVACID included <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">contusion</span>, <span class="product-label-link" type="condition" conceptid="433516" conceptname="Duodenitis">duodenitis</span>, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">epigastric discomfort</span>, <span class="product-label-link" type="condition" conceptid="31610" conceptname="Disorder of esophagus">esophageal disorder</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span>, <span class="product-label-link" type="condition" conceptid="4224004" conceptname="Hiatal hernia">hiatal hernia</span>, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>, <span class="product-label-link" type="condition" conceptid="4010028" conceptname="Impaired gastric emptying">impaired gastric emptying</span>, <span class="product-label-link" type="condition" conceptid="4070551" conceptname="Metaplasia">metaplasia</span>, and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>Additional adverse experiences occurring in less than 1% of patients or subjects who received PREVACID in domestic trials are shown below:</p>
<p><span class="Italics">Body as a Whole</span> – <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdomen enlarged</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span>, carcinoma, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> (not otherwise specified), <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>, <span class="product-label-link" type="condition" conceptid="4195873" conceptname="Breath smells unpleasant">halitosis</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (not otherwise specified), <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>, <span class="product-label-link" type="condition" conceptid="4228784" conceptname="Nuchal rigidity">neck rigidity</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span> </p>
<p><span class="Italics">Cardiovascular System – </span>angina, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>/<span class="product-label-link" type="condition" conceptid="443454" conceptname="Cerebral infarction">cerebral infarction</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>/<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> (<span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">circulatory failure</span>), <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, vasodilation</p>
<p><span class="Italics">Digestive System –</span> <span class="product-label-link" type="condition" conceptid="437671" conceptname="Abnormal feces">abnormal stools</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4198551" conceptname="Bezoar">bezoar</span>, <span class="product-label-link" type="condition" conceptid="318186" conceptname="Achalasia of esophagus">cardiospasm</span>, <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="4268622" conceptname="Stricture of esophagus">esophageal stenosis</span>, <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulcer</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, fecal discoloration, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, gastric <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span>/fundic gland <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="198249" conceptname="Congenital anomaly of digestive system">gastrointestinal anomaly</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorder</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">gum hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">increased salivation</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="193133" conceptname="Gastrointestinal candidiasis">gastrointestinal moniliasis</span>, <span class="product-label-link" type="condition" conceptid="79069" conceptname="Disorder of rectum">rectal disorder</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, tenesmus, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="432941" conceptname="Disorder of tongue">tongue disorder</span>, <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, <span class="product-label-link" type="condition" conceptid="4160872" conceptname="Recurrent aphthous ulcer">ulcerative stomatitis</span></p>
<p><span class="Italics">Endocrine System –</span> <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span>, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> </p>
<p><span class="Italics">Hemic and Lymphatic System –</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span></p>
<p><span class="Italics">Metabolic and Nutritional Disorders –</span> <span class="product-label-link" type="condition" conceptid="436658" conceptname="Vitamin deficiency">avitaminosis</span>, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>/<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>/loss</p>
<p><span class="Italics">Musculoskeletal System –</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="75909" conceptname="Disorder of bone">bone disorder</span>, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">joint disorder</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">myasthenia</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>,  <span class="product-label-link" type="condition" conceptid="4168183" conceptname="Synovitis">synovitis</span></p>
<p><span class="Italics">Nervous System –</span> <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="374022" conceptname="Hemiplegia">hemiplegia</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span> aggravated, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">libido decreased</span>/increased, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="444243" conceptname="Neurosis">neurosis</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, thinking abnormality, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Italics">Respiratory System –</span> <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough increased</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccup</span>, <span class="product-label-link" type="condition" conceptid="22274" conceptname="Neoplasm of uncertain behavior of larynx">laryngeal neoplasia</span>, <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">lung fibrosis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4338843" conceptname="Disorder of pleura">pleural disorder</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorder</span>, upper respiratory <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>/<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">stridor</span></p>
<p><span class="Italics">Skin and Appendages –</span> <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">fixed eruption</span>, <span class="product-label-link" type="condition" conceptid="4199168" conceptname="Wooly hair">hair disorder</span>, <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail disorder</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, skin carcinoma, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="Italics">Special Senses –</span> <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">amblyopia</span>, <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>, ear/<span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">eye disorder</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">parosmia</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="4090255" conceptname="Retinal drusen">retinal degeneration</span>/disorder, <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">taste loss</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span></p>
<p><span class="Italics">Urogenital System –</span> abnormal menses, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney calculus</span>, <span class="product-label-link" type="condition" conceptid="4167250" conceptname="Renal pain">kidney pain</span>, <span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">leukorrhea</span>, <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span>, <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorder</span>, <span class="product-label-link" type="condition" conceptid="196158" conceptname="Disorder of penis">penis disorder</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="4276801" conceptname="Disorder of testis">testis disorder</span>, <span class="product-label-link" type="condition" conceptid="4280509" conceptname="Pain in urethra">urethral pain</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">urinary urgency</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">urination impaired</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<p class="First">Additional adverse experiences have been reported since PREVACID has been marketed. The majority of these cases are foreign-sourced and a relationship to PREVACID has not been established. Because these reactions were reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events are listed below by COSTART body system.</p>
<p><span class="Italics">Body as a Whole - </span>anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>; <span class="Italics">Digestive System - </span>hepatotoxicity, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; <span class="Italics">Hemic and Lymphatic System - </span><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span>; <span class="Italics">Musculoskeletal System - </span><span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span>; <span class="Italics">Skin and Appendages</span> - severe dermatologic reactions including <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (some fatal); <span class="Italics">Special Senses - </span>speech disorder; <span class="Italics">Urogenital System - </span>interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3	Combination Therapy with Amoxicillin and Clarithromycin</h2>
<p class="First">In clinical trials using combination therapy with PREVACID plus amoxicillin and clarithromycin, and PREVACID plus amoxicillin, no adverse reactions peculiar to these drug combinations were observed. Adverse reactions that have occurred have been limited to those that had been previously reported with PREVACID, amoxicillin, or clarithromycin.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3.1"></a><p></p>
<p class="First"><span class="Italics">Triple Therapy:</span>  PREVACID/amoxicillin/clarithromycin</p>
<p>The most frequently reported adverse reactions for patients who received triple therapy for 14 days were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (7%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (6%), and <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span> (5%). There were no statistically significant differences in the frequency of reported adverse reactions between the 10- and 14-day triple therapy regimens. No treatment-emergent adverse reactions were observed at significantly higher rates with triple therapy than with any dual therapy regimen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3.2"></a><p></p>
<p class="First"><span class="Italics">Dual Therapy:</span>  PREVACID/amoxicillin</p>
<p>The most frequently reported adverse reactions for patients who received PREVACID three times daily plus amoxicillin three times daily dual therapy were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (8%) and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (7%). No treatment-emergent adverse reactions were observed at significantly higher rates with PREVACID three times daily plus amoxicillin three times daily dual therapy than with PREVACID alone.</p>
<p>For information on adverse reactions with amoxicillin or clarithromycin, refer to their full prescribing information, ADVERSE REACTIONS sections.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.4"></a><a name="section-6.4"></a><p></p>
<h2>6.4	Laboratory Values</h2>
<p class="First">The following changes in laboratory parameters in patients who received PREVACID were reported as adverse reactions:</p>
<p><span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">Abnormal liver function tests</span>, increased <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> (AST), increased SGPT (ALT), increased creatinine, increased alkaline phosphatase, increased globulins, increased GGTP, increased/decreased/abnormal WBC, abnormal AG ratio, abnormal RBC, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">bilirubinemia</span>, <span class="product-label-link" type="condition" conceptid="4107462" conceptname="k">blood potassium</span> increased, blood urea increased, crystal urine present, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">hemoglobin decreased</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipemia</span>, increased/decreased electrolytes, increased/decreased <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, increased glucocorticoids, increased LDH, increased/decreased/<span class="product-label-link" type="condition" conceptid="4332151" conceptname="Platelet disorder">abnormal platelets</span>, increased gastrin levels and positive fecal occult blood. Urine abnormalities such as <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, and <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> were also reported. Additional isolated laboratory abnormalities were reported.</p>
<p>In the placebo controlled studies, when <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> (AST) and SGPT (ALT) were evaluated, 0.4% (4/978) and 0.4% (11/2677) patients, who received placebo and PREVACID, respectively, had enzyme elevations greater than three times the upper limit of normal range at the final treatment visit. None of these patients who received PREVACID reported <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> at any time during the study.</p>
<p>In clinical trials using combination therapy with PREVACID plus amoxicillin and clarithromycin, and PREVACID plus amoxicillin, no increased laboratory abnormalities particular to these drug combinations were observed.</p>
<p>For information on laboratory value changes with amoxicillin or clarithromycin, refer to their full prescribing information, ADVERSE REACTIONS sections.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7	DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<p class="First"><span class="Bold">Drugs with pH-Dependent Absorption Kinetics</span></p>
<p>PREVACID causes long-lasting inhibition of gastric acid secretion. PREVACID and other PPIs are likely to substantially decrease the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance. Therefore, PREVACID and other PPIs should not be co-administered with atazanavir <span class="Italics">[see <a href="#S12.5">Clinical Pharmacology (12.5)</a>]</span>. 								</p>
<p>It is theoretically possible that PREVACID and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole)<span class="Italics"> [see <a href="#S12.5">Clinical Pharmacology (12.5)</a>]</span>. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<p class="First"><span class="Bold">Warfarin</span></p>
<p>In a study of healthy subjects, co-administration of single or multiple 60 mg doses of PREVACID and warfarin did not affect the pharmacokinetics of warfarin nor <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time [<span class="Italics">see <a href="#S12.5">Clinical Pharmacology (12.5)</a>]</span>. However, there have been reports of increased INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients receiving PPIs and warfarin concomitantly. Increases in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time may lead to abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time <span class="Italics">[see <a href="#S12.5">Clinical Pharmacology (12.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<p class="First"><span class="Bold">Tacrolimus</span></p>
<p>									Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<p class="First"><span class="Bold">Theophylline</span></p>
<p>A minor increase (10%) in the clearance of theophylline was observed following the administration of PREVACID concomitantly with theophylline. Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when PREVACID is started or stopped to ensure clinically effective blood levels <span class="Italics">[see <a href="#S12.5">Clinical Pharmacology (12.5)</a>]</span>. 								</p>
<p>For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Teratogenic effects</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.1"></a><p></p>
<h4></h4>
<p class="First">Pregnancy Category B. Reproduction studies have been performed in pregnant rats at oral doses up to 40 times the recommended human dose and in pregnant rabbits at oral doses up to 16 times the recommended human dose and have revealed no evidence of impaired fertility or harm to the fetus due to lansoprazole. There are, however, no adequate or well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed <span class="Italics">[see<a href="#S13.2"> Nonclinical Toxicology (13.2)</a>]</span>.</p>
<p>See full prescribing information for clarithromycin before using in pregnant women.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First">Lansoprazole or its metabolites are excreted in the milk of rats. It is not known whether lansoprazole is excreted in human milk. Because many drugs are excreted in human milk, because of the potential for serious adverse reactions in nursing infants from lansoprazole, and because of the potential for tumorigenicity shown for lansoprazole in rat carcinogenicity studies, a decision should be made whether to discontinue nursing or to discontinue lansoprazole, taking into account the importance of lansoprazole to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">The safety and effectiveness of PREVACID have been established in pediatric patients 1 to 17 years of age for short-term treatment of symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> and <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>, however, PREVACID was not effective in patients with symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> 1 month to less than 1 year of age in a multicenter, double-blind, placebo controlled study. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.1"></a><p></p>
<p class="First"><span class="Bold">Neonate to less than 1 year of age</span></p>
<p>The pharmacokinetics of lansoprazole were studied in pediatric patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> aged less than 28 days and 1 to 11 months. Compared to healthy adults receiving 30 mg, neonates had higher exposure (mean weight-based normalized AUC values 2.04- and 1.88-fold higher at doses of 0.5 mg/kg/day and 1 mg/kg/day, respectively). Infants aged ≤10 weeks had clearance and exposure values that were similar to neonates. Infants aged greater than 10 weeks who received 1 mg/kg/day had mean AUC values that were similar to adults who received a 30 mg dose.</p>
<p>Lansoprazole was not found to be effective in a U.S. and Polish 4 week multicenter, double-blind, placebo-controlled, parallel-group study of 162 patients between one month and less than 12 months of age with symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> based on a medical history of <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>/fussing/<span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> associated with feedings who had not responded to conservative <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> management (i.e., non-pharmacologic intervention) for 7 to 14 days. Patients received lansoprazole as a suspension daily (0.2 to 0.3 mg/kg/day in infants ≤10 weeks of age or 1.0 to 1.5 mg/kg/day in infants greater than 10 weeks or placebo) for up to 4 weeks of double-blind treatment. </p>
<p>The primary efficacy endpoint was assessed by greater than 50% reduction from baseline in either the percent of feedings with a <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>/fussing/<span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> episode or the duration (minutes) of a <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>/fussing/<span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> episode within one hour after feeding. </p>
<p>There was no difference in the percentage of responders between the lansoprazole pediatric suspension group and placebo group (54% in both groups).</p>
<p>There were no adverse events reported in pediatric clinical studies (1 month to less than 12 months of age) that were not previously observed in adults. </p>
<p>Based on the results of the Phase 3 efficacy study, lansoprazole was not shown to be effective. Therefore, these results do not support the use of lansoprazole in treating symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in infants.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.2"></a><p></p>
<p class="First"><span class="Bold">One to 11 years of age</span></p>
<p>In an uncontrolled, open-label, U.S. multicenter study, 66 pediatric patients (1 to 11 years of age) with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> were assigned, based on body weight, to receive an initial dose of either PREVACID 15 mg daily if ≤30 kg or PREVACID 30 mg daily if greater than 30 kg administered for 8 to 12 weeks. The PREVACID dose was increased (up to 30 mg twice daily) in 24 of 66 pediatric patients after 2 or more weeks of treatment if they remained symptomatic. At baseline 85% of patients had mild to moderate overall <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> symptoms (assessed by investigator interview), 58% had non-erosive <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> and 42% had <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> (assessed by endoscopy).</p>
<p>After 8 to 12 weeks of PREVACID treatment, the intent-to-treat analysis demonstrated an approximate 50% reduction in frequency and severity of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> symptoms.</p>
<p>Twenty-one of 27 <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> patients were healed at 8 weeks and 100% of patients were healed at 12 weeks by endoscopy (Table 2).</p>
<a name="table2"></a><table width="80%">
<caption><span>Table 2: <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> Symptom Improvement and <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> Healing Rates in Pediatric Patients Age 1 to 11</span></caption>
<col align="left" valign="middle" width="60%">
<col align="center" valign="middle" width="40%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span></th>
<th class="Rrule" align="center">Final Visit<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a> % (n/N)</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>At Week 8 or Week 12</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>Symptoms assessed by patients diary kept by caregiver.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">‡</a></dt>
<dd>No data were available for 4 pediatric patients.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span><br>  Improvement in Overall <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> Symptoms<a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a>
</td>
<td class="Rrule" align="center">
<br>  76% (47/62<a name="footnote-reference-8" href="#footnote-8" class="Sup">‡</a>)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span><br>  Improvement in Overall <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> Symptoms<a href="#footnote-7" class="Sup">†</a><br>  Healing Rate</td>
<td class="Rrule" align="center">
<br>  81% (22/27)<br>  100% (27/27)</td>
</tr>
</tbody>
</table>
<p>In a study of 66 pediatric patients in the age group 1 year to 11 years old after treatment with PREVACID given orally in doses of 15 mg daily to 30 mg twice daily, increases in serum gastrin levels were similar to those observed in adult studies. Median fasting serum gastrin levels increased 89% from </p>
<p>51 pg/mL at baseline to 97 pg/mL [interquartile range (25<span class="Sup">th</span> to 75<span class="Sup">th</span> percentile) of 71 to 130 pg/mL] at the final visit.</p>
<p>The pediatric safety of PREVACID Delayed-Release Capsules has been assessed in 66 pediatric patients aged 1 to 11 years of age. Of the 66 patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> 85% (56/66) took PREVACID for 8 weeks and 15% (10/66) took it for 12 weeks.</p>
<p>The most frequently reported (2 or more patients) treatment-related adverse reactions in patients 1 to 11 years of age (N=66) were <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (5%) and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (3%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.3"></a><p></p>
<p class="First"><span class="Bold">Twelve to 17 years of age</span></p>
<p>In an uncontrolled, open-label, U.S. multicenter study, 87 adolescent patients (12 to 17 years of age) with symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> were treated with PREVACID for 8 to 12 weeks.  Baseline upper endoscopies classified these patients into two groups: 64 (74%) nonerosive <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> and 23 (26%) <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> (EE). The nonerosive <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> patients received PREVACID 15 mg daily for 8 weeks and the EE patients received PREVACID 30 mg daily for 8 to 12 weeks. At baseline, 89% of these patients had mild to moderate overall <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> symptoms (assessed by investigator interviews). During 8 weeks of PREVACID treatment, adolescent patients experienced a 63% reduction in frequency and a 69% reduction in severity of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> symptoms based on diary results.</p>
<p>Twenty-one of 22 (95.5%) adolescent <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> patients were healed after 8 weeks of PREVACID treatment. One patient remained unhealed after 12 weeks of treatment (Table 3).</p>
<a name="table3"></a><table width="80%">
<caption><span>Table 3: <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> Symptom Improvement and <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> Healing Rates in Pediatric Patients Age 12 to 17</span></caption>
<col align="left" valign="middle" width="60%">
<col align="center" valign="middle" width="40%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span></th>
<th class="Rrule" align="center">Final Visit % (n/N)</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>Symptoms assessed by patient diary (parents/caregivers as necessary).</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">†</a></dt>
<dd>No data available for 5 patients.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">‡</a></dt>
<dd>Data from one healed patient was excluded from this analysis due to timing of final endoscopy.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> (All Patients)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Improvement in Overall <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> Symptoms<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a>
</td>
<td class="Rrule" align="center">73.2% (60/82)<a name="footnote-reference-10" href="#footnote-10" class="Sup">†</a>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Nonerosive <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Improvement in Overall <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> Symptoms<a href="#footnote-9" class="Sup">*</a>
</td>
<td class="Rrule" align="center">71.2% (42/59)<a href="#footnote-10" class="Sup">†</a>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Improvement in Overall <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> Symptoms<a href="#footnote-9" class="Sup">*</a>
</td>
<td class="Rrule" align="center">78.3% (18/23)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Healing Rate<a name="footnote-reference-11" href="#footnote-11" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">95.5% (21/22)<a href="#footnote-11" class="Sup">‡</a>
</td>
</tr>
</tbody>
</table>
<p>In these 87 adolescent patients, increases in serum gastrin levels were similar to those observed in adult studies, median fasting serum gastrin levels increased 42% from 45 pg/mL at baseline to 64 pg/mL [interquartile range (25<span class="Sup">th</span> to 75<span class="Sup">th</span> percentile) of 44 to 88 pg/mL] at the final visit. (Normal serum gastrin levels are 25 to 111 pg/mL.)</p>
<p>The safety of PREVACID Delayed-Release Capsules has been assessed in these 87 adolescent patients. Of the 87 adolescent patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>, 6% (5/87) took PREVACID for less than 6 weeks, 93% (81/87) for 6 to 10 weeks, and 1% (1/87) for greater than 10 weeks.</p>
<p>The most frequently reported (at least 3%) treatment-related adverse reactions in these patients were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (7%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (3%) and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (3%). Treatment-related <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, reported in this package insert as occurring in less than 1% of adult patients, was reported in this study by 3 adolescent patients with nonerosive <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>, who had <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> concurrently with other reactions (such as <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>). </p>
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5	Geriatric Use</h2>
<p class="First">No dosage adjustment of PREVACID is necessary in geriatric patients. The incidence rates of PREVACID-associated adverse reactions and laboratory test abnormalities are similar to those seen in younger patients <span class="Italics">[see <a href="#S12.4">Clinical Pharmacology (12.4)</a>]</span>. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dosage adjustment of PREVACID is necessary in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The pharmacokinetics of lansoprazole in patients with various degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> were not substantially different compared to those in subjects with normal renal function <span class="Italics">[see <a href="#S12.4">Clinical Pharmacology (12.4)</a>]</span>. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">In patients with various degrees of chronic <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, an increase in the mean AUC of up to 500% was observed at steady state compared to healthy subjects. Consider dose reduction in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#S12.4">Clinical Pharmacology (12.4)</a>]</span>. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.8"></a><a name="section-8.7"></a><p></p>
<h2>8.8	Gender</h2>
<p class="First">Over 4,000 women were treated with PREVACID. <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcer</span> healing rates in females were similar to those in males. The incidence rates of adverse reactions in females were similar to those seen in males <span class="Italics">[see <a href="#S12.4">Clinical Pharmacology (12.4)</a>]</span>. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.9"></a><a name="section-8.8"></a><p></p>
<h2>8.9	Race</h2>
<p class="First">The pooled mean pharmacokinetic parameters of PREVACID from twelve U.S. Phase 1 studies (N=513) were compared to the mean pharmacokinetic parameters from two Asian studies (N=20). The mean AUCs of PREVACID in Asian subjects were approximately twice those seen in pooled U.S. data; however, the inter-individual variability was high. The C<span class="Sub">max</span> values were comparable.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10	OVERDOSAGE</h1>
<p class="First">PREVACID is not removed from the circulation by hemodialysis. In one reported <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, a patient consumed 600 mg of PREVACID with no adverse reaction. Oral PREVACID doses up to 5000 mg/kg in rats [approximately 1300 times the 30 mg human dose based on body surface area (BSA)] and in mice (about 675.7 times the 30 mg human dose based on BSA) did not produce <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> or any clinical signs.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11	DESCRIPTION</h1>
<p class="First">The active ingredient in PREVACID Delayed-Release Capsulesand PREVACID SoluTab Delayed-Release Orally Disintegrating Tablets is lansoprazole, a substituted benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl] methyl] sulfinyl] benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formula is C<span class="Sub">16</span>H<span class="Sub">14</span>F<span class="Sub">3</span>N<span class="Sub">3</span>O<span class="Sub">2</span>S with a molecular weight of 369.37. PREVACID has the following structure:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7140f8d9-e478-4f69-a4eb-3fd4c9414576&amp;name=prevacid-01.jpg"></div>
<p>Lansoprazole is a white to brownish-white odorless crystalline powder which melts with decomposition at approximately 166°C. Lansoprazole is freely soluble in dimethylformamide; soluble in methanol; sparingly soluble in ethanol; slightly soluble in ethyl acetate, dichloromethane and acetonitrile; very slightly soluble in ether; and practically insoluble in hexane and water.</p>
<p>Lansoprazole is stable when exposed to light for up to two months. The rate of degradation of the compound in aqueous solution increases with decreasing pH. The degradation half-life of the drug substance in aqueous solution at 25°C is approximately 0.5 hour at pH 5.0 and approximately 18 hours at pH 7.0.</p>
<p>PREVACID is supplied in delayed-release capsules and in delayed-release orally disintegrating tablets for oral administration. </p>
<p>The delayed-release capsules are available in two dosage strengths: 15 mg and 30 mg of lansoprazole per capsule. Each delayed-release capsule contains enteric-coated granules consisting of 15 mg or 30 mg of lansoprazole (active ingredient) and the following inactive ingredients: sugar sphere, sucrose, methacrylic acid copolymer, low substituted hydroxypropyl cellulose, starch, magnesium carbonate, talc, polyethylene glycol, titanium dioxide, polysorbate 80, hydroxypropyl cellulose, colloidal silicon dioxide, D&amp;C Red No. 28, FD&amp;C Blue No. 1, FD&amp;C Green No. 3<a name="footnote-reference-12" href="#footnote-12" class="Sup">1</a>, and FD&amp;C Red No. 40.</p>
<p>PREVACID SoluTab Delayed-Release Orally Disintegrating Tablets are available in two dosage strengths: 15 mg and 30 mg of lansoprazole per tablet. Each delayed-release orally disintegrating tablet contains enteric-coated microgranules consisting of 15 mg or 30 mg of lansoprazole (active ingredient) and the following inactive ingredients: mannitol, methacrylic acid, hydroxypropyl cellulose, lactose monohydrate-microcrystalline cellulose sphere, triethyl citrate, crospovidone, polyacrylate, magnesium carbonate, aspartame<a name="footnote-reference-13" href="#footnote-13" class="Sup">2</a>, glyceryl monostearate, hypromellose, magnesium stearate, citric acid, titanium dioxide, talc, artificial strawberry flavor, polyethylene glycol, polysorbate 80 and ferric oxide.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-12" href="#footnote-reference-12">1</a></dt>
<dd>PREVACID 15-mg capsules only.</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">2</a></dt>
<dd><span class="Bold">Phenylketonurics: Contains Phenylalanine 2.5 mg per 15 mg Tablet and 5.1 mg per 30 mg Tablet.</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">PREVACID (lansoprazole) belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H<span class="Sup">+</span>, K<span class="Sup">+</span>)-ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the parietal cell, lansoprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. Lansoprazole does not exhibit anticholinergic or histamine type-2 antagonist activity. </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2	Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Italics">Antisecretory Activity: </span>After oral administration, lansoprazole was shown to significantly decrease the basal acid output and significantly increase the mean gastric pH and percent of time the gastric pH was greater than 3 and greater than 4. Lansoprazole also significantly reduced meal-stimulated gastric acid output and secretion volume, as well as pentagastrin-stimulated acid output. In patients with hypersecretion of acid, lansoprazole significantly reduced basal and pentagastrin-stimulated gastric acid secretion. Lansoprazole inhibited the normal increases in secretion volume, acidity and acid output induced by insulin. </p>
<p>The intragastric pH results of a five-day, pharmacodynamic, crossover study of 15 mg and 30 mg of once daily lansoprazole are presented in Table 4:</p>
<a name="table4"></a><table width="100%">
<caption><span>Table 4: Mean Antisecretory Effects After Single and Multiple Daily PREVACID Dosing</span></caption>
<col align="left" valign="middle" width="28%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="14%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" colspan="2"></th>
<th class="Rrule" align="center" colspan="4">PREVACID</th>
</tr>
<tr class="Botrule">
<th class="Lrule Rrule" align="left" rowspan="2">Parameter</th>
<th class="Rrule" align="center" rowspan="2">Baseline Value</th>
<th class="Rrule" align="center" colspan="2">15 mg</th>
<th class="Rrule" align="center" colspan="2">30 mg</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">Day 1</th>
<th class="Rrule Toprule" align="center">Day 5</th>
<th class="Rrule" align="center">Day 1</th>
<th class="Rrule" align="center">Day 5</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="6">NOTE:  An intragastric pH of greater than 4 reflects a reduction in gastric acid by 99%.</td></tr>
<tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>(p&lt;0.05) versus baseline only.</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">†</a></dt>
<dd>(p&lt;0.05) versus baseline and lansoprazole 15 mg.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Mean 24 Hour pH</td>
<td class="Rrule" align="center">2.1</td>
<td class="Rrule" align="center">2.7<a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a>
</td>
<td class="Rrule" align="center">4.0<a href="#footnote-14" class="Sup">*</a>
</td>
<td class="Rrule" align="center">3.6<a name="footnote-reference-15" href="#footnote-15" class="Sup">†</a>
</td>
<td class="Rrule" align="center">4.9<a href="#footnote-15" class="Sup">†</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Mean Nighttime pH</td>
<td class="Rrule" align="center">1.9</td>
<td class="Rrule" align="center">2.4</td>
<td class="Rrule" align="center">3.0<a href="#footnote-14" class="Sup">*</a>
</td>
<td class="Rrule" align="center">2.6</td>
<td class="Rrule" align="center">3.8<a href="#footnote-15" class="Sup">†</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">% Time Gastric pH&gt;3</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">33<a href="#footnote-14" class="Sup">*</a>
</td>
<td class="Rrule" align="center">59<a href="#footnote-14" class="Sup">*</a>
</td>
<td class="Rrule" align="center">51<a href="#footnote-15" class="Sup">†</a>
</td>
<td class="Rrule" align="center">72<a href="#footnote-15" class="Sup">†</a>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">% Time Gastric pH&gt;4</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">22<a href="#footnote-14" class="Sup">*</a>
</td>
<td class="Rrule" align="center">49<a href="#footnote-14" class="Sup">*</a>
</td>
<td class="Rrule" align="center">41<a href="#footnote-15" class="Sup">†</a>
</td>
<td class="Rrule" align="center">66<a href="#footnote-15" class="Sup">†</a>
</td>
</tr>
</tbody>
</table>
<p>After the initial dose in this study, increased gastric pH was seen within 1 to 2 hours with 30 mg of lansoprazole and 2 to 3 hours with 15 mg of lansoprazole. After multiple daily dosing, increased gastric pH was seen within the first hour post-dosing with 30 mg of lansoprazole and within 1 to 2 hours post-dosing with 15 mg of lansoprazole.</p>
<p>Acid suppression may enhance the effect of antimicrobials in eradicating <span class="Italics">Helicobacter pylori</span> (<span class="Italics">H. pylori</span>). The percentage of time gastric pH was elevated above 5 and 6 was evaluated in a crossover study of PREVACID given daily, twice daily and three times daily (Table 5).</p>
<a name="table5"></a><table width="100%">
<caption><span>Table 5: Mean Antisecretory Effects After 5 Days of Twice Daily and Three Times Daily Dosing</span></caption>
<col align="left" valign="middle" width="26%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="23%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="4">PREVACID</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">Parameter</th>
<th class="Rrule" align="center">30 mg daily</th>
<th class="Rrule" align="center">15 mg twice daily</th>
<th class="Rrule" align="center">30 mg twice daily</th>
<th class="Rrule" align="center">30 mg three times daily</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-16" href="#footnote-reference-16">*</a></dt>
<dd>(p&lt;0.05) versus PREVACID 30 mg daily</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">†</a></dt>
<dd>(p&lt;0.05) versus PREVACID 30 mg daily, 15 mg twice daily and 30 mg twice daily.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">% Time Gastric pH&gt;5</td>
<td class="Rrule" align="center">43</td>
<td class="Rrule" align="center">47</td>
<td class="Rrule" align="center">59<a name="footnote-reference-16" href="#footnote-16" class="Sup">*</a>
</td>
<td class="Rrule" align="center">77<a name="footnote-reference-17" href="#footnote-17" class="Sup">†</a>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">% Time Gastric pH&gt;6</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">45<a href="#footnote-17" class="Sup">†</a>
</td>
</tr>
</tbody>
</table>
<p>The inhibition of gastric acid secretion as measured by intragastric pH gradually returned to normal over two to four days after multiple doses. There was no indication of rebound gastric acidity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Italics">Enterochromaffin-like (ECL) Cell Effects</span></p>
<p>During lifetime exposure of rats with up to 150 mg/kg/day of lansoprazole dosed seven days per week, marked <span class="product-label-link" type="condition" conceptid="4245637" conceptname="Hypergastrinemia">hypergastrinemia</span> was observed followed by ECL cell proliferation and formation of <span class="product-label-link" type="condition" conceptid="4304399" conceptname="Carcinoid tumor">carcinoid tumors</span>, especially in female rats. Gastric biopsy specimens from the body of the stomach from approximately 150 patients treated continuously with lansoprazole for at least one year did not show evidence of ECL cell effects similar to those seen in rat studies. Longer term data are needed to rule out the possibility of an increased risk of the development of gastric tumors in patients receiving long-term therapy with lansoprazole <span class="Italics">[see <a href="#S13.1">Nonclinical Toxicology (13.1)</a>]</span>. 										</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.3"></a><p></p>
<p class="First"><span class="Italics">Other Gastric Effects in Humans</span></p>
<p>Lansoprazole did not significantly affect mucosal blood flow in the fundus of the stomach. Due to the normal physiologic effect caused by the inhibition of gastric acid secretion, a decrease of about 17% in blood flow in the antrum, pylorus, and duodenal bulb was seen. Lansoprazole significantly slowed the gastric emptying of digestible solids. Lansoprazole increased serum pepsinogen levels and decreased pepsin activity under basal conditions and in response to meal stimulation or insulin injection. As with other agents that elevate intragastric pH, increases in gastric pH were associated with increases in nitrate-reducing bacteria and elevation of nitrite concentration in gastric juice in patients with <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>. No significant increase in nitrosamine concentrations was observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.4"></a><p></p>
<p class="First"><span class="Italics">Serum Gastrin Effects</span></p>
<p>In over 2100 patients, median fasting serum gastrin levels increased 50% to 100% from baseline but remained within normal range after treatment with 15 to 60 mg of oral lansoprazole. These elevations reached a plateau within two months of therapy and returned to pretreatment levels within four weeks after discontinuation of therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5"></a><p></p>
<p class="First"><span class="Italics">Endocrine Effects</span></p>
<p>Human studies for up to one year have not detected any clinically significant effects on the endocrine system. Hormones studied include testosterone, luteinizing hormone (LH), follicle stimulating hormone (FSH), <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">sex hormone binding globulin</span> (SHBG), dehydroepiandrosterone sulfate (DHEA-S), prolactin, cortisol, estradiol, insulin, aldosterone, parathormone, glucagon, thyroid stimulating hormone (TSH), triiodothyronine (T<span class="Sub">3</span>), thyroxine (T<span class="Sub">4</span>), and somatotropic hormone (STH). Lansoprazole in oral doses of 15 to 60 mg for up to one year had no clinically significant effect on sexual function. In addition, lansoprazole in oral doses of 15 to 60 mg for two to eight weeks had no clinically significant effect on thyroid function. In 24-month carcinogenicity studies in Sprague-Dawley rats with daily lansoprazole dosages up to 150 mg/kg, proliferative changes in the Leydig cells of the testes, including <span class="product-label-link" type="condition" conceptid="4305589" conceptname="Neoplasm, benign">benign neoplasm</span>, were increased compared to control rats.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.6"></a><p></p>
<p class="First"><span class="Italics">Other Effects</span></p>
<p>No systemic effects of lansoprazole on the central nervous system, lymphoid, hematopoietic, renal, hepatic, cardiovascular, or respiratory systems have been found in humans. Among 56 patients who had extensive baseline eye evaluations, no visual toxicity was observed after lansoprazole treatment (up to 180 mg/day) for up to 58 months. After lifetime lansoprazole exposure in rats, focal pancreatic <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, diffuse lymphoid <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> in the thymus, and spontaneous <span class="product-label-link" type="condition" conceptid="4090255" conceptname="Retinal drusen">retinal atrophy</span> were seen.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="section-11.2.7"></a><p></p>
<p class="First"><span class="Italics">Microbiology</span></p>
<p>Lansoprazole, clarithromycin and/or amoxicillin have been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Helicobacter pylori in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the INDICATIONS AND USAGE section <span class="Italics">[see <a href="#S1.2">Indications and Usage (1.2)</a>]</span>. 										</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.7.1"></a><p></p>
<p class="First"><span class="Italics">Helicobacter pylori Pretreatment Resistance</span></p>
<p>Clarithromycin pretreatment resistance (≥2.0 mcg/mL) was 9.5% (91/960) by E-test and 11.3% (12/106) by agar dilution in the dual and triple therapy clinical trials (M93-125, M93-130, M93-131, M95-392, and M95-399).</p>
<p>Amoxicillin pretreatment susceptible isolates (≤0.25 mcg/mL) occurred in 97.8% (936/957) and 98.0% (98/100) of the patients in the dual and triple therapy clinical trials by E-test and agar dilution, respectively. Twenty-one of 957 patients (2.2%) by E-test, and 2 of 100 patients (2.0%) by agar dilution, had amoxicillin pretreatment MICs of greater than 0.25 mcg/mL. One patient on the 14-day triple therapy regimen had an unconfirmed pretreatment amoxicillin <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) of greater than 256 mcg/mL by E-test and the patient was eradicated of <span class="Italics">H. pylori </span>(Table 6)<span class="Italics">.</span></p>
<a name="table6"></a><table width="80%">
<caption><span>Table 6: Clarithromycin Susceptibility Test Results and Clinical/Bacteriological Outcomes<a name="footnote-reference-18" href="#footnote-18" class="Sup">*</a></span></caption>
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="22%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" colspan="2">Clarithromycin Pretreatment Results</th>
<th class="Rrule" align="center" colspan="5">Clarithromycin Post-treatment Results</th>
</tr>
<tr>
<th class="Lrule Rrule" align="center" colspan="2"></th>
<th class="Rrule" align="center">
<span class="Italics">H. pylori</span> negative - eradicated</th>
<th class="Botrule Rrule" align="center" colspan="4">
<span class="Italics">H. pylori</span> positive – not eradicated<br>Post-treatment susceptibility results</th>
</tr>
<tr class="Last">
<th class="Lrule" align="center"></th>
<th class="Rrule" align="center"></th>
<th class="Rrule" align="center"></th>
<th class="Rrule" align="center">S<a name="footnote-reference-19" href="#footnote-19" class="Sup">†</a>
</th>
<th class="Rrule" align="center">I<a href="#footnote-19" class="Sup">†</a>
</th>
<th class="Rrule" align="center">R<a href="#footnote-19" class="Sup">†</a>
</th>
<th class="Rrule" align="center">No MIC</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-18" href="#footnote-reference-18">*</a></dt>
<dd>Includes only patients with pretreatment clarithromycin susceptibility test results</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">†</a></dt>
<dd>Susceptible (S) MIC ≤0.25 mcg/mL, Intermediate (I) MIC 0.5 to 1.0 mcg/mL, Resistant (R) MIC ≥2 mcg/mL</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="7">Triple Therapy 14-Day (lansoprazole 30 mg twice daily/amoxicillin 1 g twice daily/clarithromycin 500 mg twice daily)<br> (M95-399, M93-131, M95-392)</td></tr>
<tr>
<td class="Lrule Rrule" align="left">Susceptible<a href="#footnote-19" class="Sup">†</a>
</td>
<td class="Rrule" align="center">112</td>
<td class="Botrule Rrule" align="center">105</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left">Intermediate<a href="#footnote-19" class="Sup">†</a>
</td>
<td class="Rrule Toprule" align="center">3</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Resistant<a href="#footnote-19" class="Sup">†</a>
</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7">Triple Therapy 10-Day (lansoprazole 30 mg twice daily/amoxicillin 1 g twice daily/clarithromycin 500 mg twice daily) <br> (M95-399)</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Susceptible<a href="#footnote-19" class="Sup">†</a>
</td>
<td class="Rrule" align="center">42</td>
<td class="Rrule" align="center">40</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Intermediate<a href="#footnote-19" class="Sup">†</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Resistant<a href="#footnote-19" class="Sup">†</a>
</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center"></td>
</tr>
</tbody>
</table>
<p>Patients not eradicated of <span class="Italics">H. pylori</span> following lansoprazole/amoxicillin/clarithromycin triple therapy will likely have clarithromycin resistant <span class="Italics">H. pylori.</span> Therefore, for those patients who fail therapy, clarithromycin susceptibility testing should be done when possible. Patients with clarithromycin resistant <span class="Italics">H. pylori</span> should not be treated with lansoprazole/amoxicillin/clarithromycin triple therapy or with regimens which include clarithromycin as the sole antimicrobial agent.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.7.2"></a><p></p>
<p class="First"><span class="Italics">Amoxicillin Susceptibility Test Results and Clinical/Bacteriological Outcomes: </span>In the dual and triple therapy clinical trials, 82.6% (195/236) of the patients that had pretreatment amoxicillin susceptible MICs (≤0.25 mcg/mL) were eradicated of <span class="Italics">H. pylori</span>. Of those with pretreatment amoxicillin MICs of greater than 0.25 mcg/mL, three of six had the <span class="Italics">H. pylori</span> eradicated. A total of 30% (21/70) of the patients failed lansoprazole 30 mg three times daily/amoxicillin 1 g three times daily dual therapy and a total of 12.8% (22/172) of the patients failed the 10- and 14-day triple therapy regimens. Post-treatment susceptibility results were not obtained on 11 of the patients who failed therapy. Nine of the 11 patients with amoxicillin post-treatment MICs that failed the triple therapy regimen also had clarithromycin resistant <span class="Italics">H. pylori</span> isolates.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.7.3"></a><p></p>
<p class="First"><span class="Italics">Susceptibility Test for Helicobacter pylori: </span>The reference methodology for susceptibility testing of <span class="Italics">H. pylori</span> is agar dilution MICs.<span class="Sup">1</span>  One to three microliters of an inoculum equivalent to a No. 2 McFarland standard (1 × 10<span class="Sup">7 </span> to 1 × 10<span class="Sup">8 </span>CFU/mL for <span class="Italics">H. pylori</span>) are inoculated directly onto freshly prepared antimicrobial-containing Mueller-Hinton agar plates with 5% aged defibrinated sheep blood (≥2 weeks old). The agar dilution plates are incubated at 35°C in a microaerobic environment produced by a gas generating system suitable for campylobacters.</p>
<p>After 3 days of incubation, the MICs are recorded as the lowest concentration of antimicrobial agent required to inhibit growth of the organism. The clarithromycin and amoxicillin MIC values should be interpreted according to the following criteria (Table 7):</p>
<a name="iaabda231-0cd8-457a-848b-29dca967aa0b"></a><table width="80%">
<caption><span>Table 7</span></caption>
<col align="center" valign="middle" width="50%">
<col align="center" valign="middle" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Clarithromycin MIC<br> (mcg/mL)<a name="footnote-reference-20" href="#footnote-20" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Interpretation</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-20" href="#footnote-reference-20">*</a></dt>
<dd>These are tentative breakpoints for the agar dilution methodology and they should not be used to interpret results obtained using alternative methods.</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">†</a></dt>
<dd>There were not enough organisms with MICs greater than 0.25 mcg/mL to determine a resistance breakpoint.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">≤0.25</td>
<td class="Rrule" align="center">Susceptible (S)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">0.5-1.0</td>
<td class="Rrule" align="center">Intermediate (I)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">≥2.0</td>
<td class="Rrule" align="center">Resistant (R)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Amoxicillin MIC <br> (mcg/mL)<a href="#footnote-20" class="Sup">*</a>,<a name="footnote-reference-21" href="#footnote-21" class="Sup">†</a>
</td>
<td class="Rrule" align="center">Interpretation</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">≤0.25</td>
<td class="Rrule" align="center">Susceptible (S)</td>
</tr>
</tbody>
</table>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard clarithromycin and amoxicillin powders should provide the following MIC values (Table 8):</p>
<a name="table8"></a><table width="80%">
<caption><span>Table 8</span></caption>
<col align="center" valign="middle" width="33%">
<col align="center" valign="middle" width="34%">
<col align="center" valign="middle" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Microorganism</th>
<th class="Rrule" align="center">Antimicrobial Agent</th>
<th class="Rrule" align="center">MIC (mcg/mL)<a name="footnote-reference-22" href="#footnote-22" class="Sup">*</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-22" href="#footnote-reference-22">*</a></dt>
<dd>These are quality control ranges for the agar dilution methodology and they should not be used to control test results obtained using alternative methods.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">
<span class="Italics">H. pylori</span> ATCC 43504</td>
<td class="Rrule" align="center">Clarithromycin</td>
<td class="Rrule" align="center">0.015-0.12</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">
<span class="Italics">H. pylori</span> ATCC 43504</td>
<td class="Rrule" align="center">Amoxicillin</td>
<td class="Rrule" align="center">0.015-0.12</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3	Pharmacokinetics</h2>
<p class="First">PREVACID Delayed-Release Capsules and PREVACID SoluTab Delayed-Release Orally Disintegrating Tablets contain an enteric-coated granule formulation of lansoprazole. Absorption of lansoprazole begins only after the granules leave the stomach. Absorption is rapid, with mean peak plasma levels of lansoprazole occurring after approximately 1.7 hours. After a single-dose administration of 15 mg to 60 mg of oral lansoprazole, the peak plasma concentrations (C<span class="Sub">max</span>) of lansoprazole and the area under the plasma concentration curves (AUCs) of lansoprazole were approximately proportional to the administered dose. Lansoprazole does not accumulate and its pharmacokinetics are unaltered by multiple dosing.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Italics">Absorption:</span> The absorption of lansoprazole is rapid, with the mean C<span class="Sub">max</span> occurring approximately 1.7 hours after oral dosing, and the absolute bioavailability is over 80%. In healthy subjects, the mean (±SD) plasma half-life was 1.5 (±1.0) hours. Both the C<span class="Sub">max</span> and AUC are diminished by about 50% to 70% if lansoprazole is given 30 minutes after food, compared to the fasting condition. There is no significant food effect if lansoprazole is given before meals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Italics">Distribution:</span> Lansoprazole is 97% bound to plasma proteins. Plasma protein binding is constant over the concentration range of 0.05 to 5.0 mcg/mL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Italics">Metabolism:</span> Lansoprazole is extensively metabolized in the liver. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of lansoprazole). These metabolites have very little or no antisecretory activity. Lansoprazole is thought to be transformed into two active species which inhibit acid secretion by blocking the proton pump [(H<span class="Sup">+</span>, K<span class="Sup">+</span>)-ATPase enzyme system] at the secretory surface of the gastric parietal cell. The two active species are not present in the systemic circulation. The plasma elimination half-life of lansoprazole is less than 2 hours while the acid inhibitory effect lasts more than 24 hours. Therefore, the plasma elimination half-life of lansoprazole does not reflect its duration of suppression of gastric acid secretion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Italics">Elimination:</span> Following single-dose oral administration of PREVACID, virtually no unchanged lansoprazole was excreted in the urine. In one study, after a single oral dose of <span class="Sup">14</span>C-lansoprazole, approximately one-third of the administered radiation was excreted in the urine and two-thirds was recovered in the feces. This implies a significant biliary excretion of the lansoprazole metabolites.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S12.4"></a><a name="section-11.4"></a><p></p>
<h2>12.4	Specific Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4.1"></a><p></p>
<p class="First"><span class="Italics">Pediatric Use: </span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4.1.1"></a><p></p>
<p class="First"><span class="Bold">One to 17 years of age</span></p>
<p>The pharmacokinetics of lansoprazole were studied in pediatric patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> aged 1 to 11 years and 12 to 17 years in two separate clinical studies. In children aged 1 to 11 years, lansoprazole was dosed 15 mg daily for subjects weighing ≤30 kg and 30 mg daily for subjects weighing greater than 30 kg. Mean C<span class="Sub">max </span>and AUC values observed on Day 5 of dosing were similar between the two dose groups and were not affected by weight or age within each weight-adjusted dose group used in the study. In adolescent subjects aged 12 to 17 years, subjects were randomized to receive lansoprazole at 15 mg or 30 mg daily. Mean C<span class="Sub">max</span> and AUC values of lansoprazole were not affected by body weight or age; and nearly dose-proportional increases in mean C<span class="Sub">max</span> and AUC values were observed between the two dose groups in the study. Overall, lansoprazole pharmacokinetics in pediatric patients aged 1 to 17 years were similar to those observed in healthy adult subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4.1.2"></a><p></p>
<p class="First"><span class="Bold">Neonate to less than one year of age</span></p>
<p>Refer to Section 8.4 for the pharmacokinetics of lansoprazole in pediatric patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> aged less than 28 days and 1 to 11 months.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4.2"></a><p></p>
<p class="First"><span class="Italics">Geriatric Use:  </span>The clearance of lansoprazole is decreased in the elderly, with elimination half-life increased approximately 50% to 100%. Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole. Peak plasma levels were not increased in the elderly. No dosage adjustment is necessary in the elderly<span class="Italics"> [see <a href="#S8.5">Use in Specific Populations (8.5)</a>]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4.3"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> In patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, plasma protein binding decreased by 1.0%- to 1.5% after administration of 60 mg of lansoprazole. Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> had a shortened elimination half-life and decreased total AUC (free and bound). The AUC for free lansoprazole in plasma, however, was not related to the degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>; and the C<span class="Sub">max</span> and T<span class="Sub">max</span> (time to reach the maximum concentration) were not different than the C<span class="Sub">max</span> and T<span class="Sub">max</span> from subjects with normal renal function. No dosage adjustment is necessary in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#S8.6">Use in Specific Populations (8.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4.4"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> In patients with various degrees of chronic <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the mean plasma half-life of lansoprazole was prolonged from 1.5 hours to 3.2 to 7.2 hours. An increase in the mean AUC of up to 500% was observed at steady state in hepatically-impaired patients compared to healthy subjects. Consider dose reduction in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#S8.7">Use in Specific Populations (8.7)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4.5"></a><p></p>
<p class="First"><span class="Italics">Gender:</span>  In a study comparing 12 male and 6 female human subjects who received lansoprazole, no gender differences were found in pharmacokinetics and intragastric pH results <span class="Italics">[see <a href="#S8.5">Use in Specific Populations (8.5)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S12.5"></a><a name="section-11.5"></a><p></p>
<h2>12.5	Drug-Drug Interactions</h2>
<p class="First">It is theoretically possible that PREVACID may interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, digoxin).</p>
<p>PREVACID is metabolized through the cytochrome P<span class="Sub">450</span> system, specifically through the CYP3A and CYP2C19 isozymes. Studies have shown that PREVACID does not have clinically significant interactions with other drugs metabolized by the cytochrome P<span class="Sub">450</span> system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects. These compounds are metabolized through various cytochrome P<span class="Sub">450</span> isozymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.5.1"></a><p></p>
<p class="First"><span class="Italics">Atazanavir: </span>PREVACID causes long-lasting inhibition of gastric acid secretion. PREVACID substantially decreases the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance. Therefore, PREVACID, or other proton pump inhibitors, should not be co-administered with atazanavir. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.5.2"></a><p></p>
<p class="First"><span class="Italics">Theophylline: </span>When PREVACID was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen. Because of the small magnitude and the direction of the effect on theophylline clearance, this interaction is unlikely to be of clinical concern. Nonetheless, individual patients may require additional titration of their theophylline dosage when PREVACID is started or stopped to ensure clinically effective blood levels.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.5.3"></a><p></p>
<p class="First"><span class="Italics">Warfarin: </span>In a study of healthy subjects neither the pharmacokinetics of warfarin enantiomers nor <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time were affected following single or multiple 60 mg doses of lansoprazole. However, there have been reports of increased International Normalized Ratio (INR) and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients receiving proton pump inhibitors, including PREVACID, and warfarin concomitantly. Increases in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time may lead to abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.5.4"></a><p></p>
<p class="First"><span class="Italics">Methotrexate and 7-hydromethotrexate: </span>In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and PREVACID 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate. While this study was not designed to assess the safety of this combination of drugs, no major adverse reactions were noted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.5.5"></a><p></p>
<p class="First"><span class="Italics">Amoxicillin: </span>PREVACID has also been shown to have no clinically significant interaction with amoxicillin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.5.6"></a><p></p>
<p class="First"><span class="Italics">Sucralfate</span>: In a single-dose crossover study examining PREVACID 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate. Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate. In clinical trials, antacids were administered concomitantly with PREVACID and there was no evidence of a change in the efficacy of PREVACID.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In two 24-month carcinogenicity studies, Sprague-Dawley rats were treated with oral lansoprazole doses of 5 to 150 mg/kg/day, about 1 to 40 times the exposure on a body surface (mg/m<span class="Sup">2</span>) basis of a 50 kg person of average height [1.46 m<span class="Sup">2</span>  body surface area (BSA)] given the recommended human dose of 30 mg/day. Lansoprazole produced dose-related gastric enterochromaffin-like (ECL) cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and ECL cell carcinoids in both male and female rats. It also increased the incidence of intestinal <span class="product-label-link" type="condition" conceptid="4070551" conceptname="Metaplasia">metaplasia</span> of the gastric epithelium in both sexes. In male rats, lansoprazole produced a dose-related increase of testicular interstitial cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span>. The incidence of these <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in rats receiving doses of 15 to 150 mg/kg/day (4 to 40 times the recommended human dose based on BSA) exceeded the low background incidence (range = 1.4 to 10%) for this <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of rat. </p>
<p>In a 24-month carcinogenicity study, CD-1 mice were treated with oral lansoprazole doses of 15 to 600 mg/kg/day, 2 to 80 times the recommended human dose based on BSA. Lansoprazole produced a dose-related increased incidence of gastric ECL cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>. It also produced an increased incidence of <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span> (<span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenoma</span> plus carcinoma). The tumor incidences in male mice treated with 300 and 600 mg/kg/day (40 to 80 times the recommended human dose based on BSA) and female mice treated with 150 to 600 mg/kg/day (20 to 80 times the recommended human dose based on BSA) exceeded the ranges of background incidences in historical controls for this <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of mice. Lansoprazole treatment produced <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span> of rete testis in male mice receiving 75 to 600 mg/kg/day (10 to 80 times the recommended human dose based on BSA).</p>
<p>A 26-week p53 (+/-) transgenic mouse carcinogenicity study was not positive.</p>
<p>Lansoprazole was not genotoxic in the Ames test, the <span class="Italics">ex vivo</span> rat hepatocyte unscheduled DNA synthesis (UDS) test, the <span class="Italics">in vivo</span> mouse micronucleus test, or the rat bone marrow cell chromosomal aberration test. It was positive in <span class="Italics">in vitro</span> human lymphocyte chromosomal aberration assays.</p>
<p>Lansoprazole at oral doses up to 150 mg/kg/day (40 times the recommended human dose based on BSA) was found to have no effect on fertility and reproductive performance of male and female rats.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="S13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2	Animal Toxicology and/or Pharmacology</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Reproductive Toxicology Studies</span></p>
<p>Reproduction studies have been performed in pregnant rats at oral lansoprazole doses up to 150 mg/kg/day [40 times the recommended human dose (30 mg/day) based on body surface area (BSA)] and pregnant rabbits at oral lansoprazole doses up to 30 mg/kg/day (16 times the recommended human dose based on BSA) and have revealed no evidence of impaired fertility or harm to the fetus due to lansoprazole.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14	CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span></span></p>
<p>In a U.S. multicenter, double-blind, placebo-controlled, dose-response (15, 30, and 60 mg of PREVACID once daily) study of 284 patients with endoscopically documented <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>, the percentage of patients healed after two and four weeks was significantly higher with all doses of PREVACID than with placebo. There was no evidence of a greater or earlier response with the two higher doses compared with PREVACID 15 mg. Based on this study and the second study described below, the recommended dose of PREVACID in <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> is 15 mg per day (Table 9).</p>
<a name="table9"></a><table width="80%">
<caption><span>Table 9: <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Healing Rates</span></caption>
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center"></th>
<th class="Botrule Rrule" align="center" colspan="3">PREVACID</th>
<th class="Rrule" align="center" rowspan="2">Placebo</th>
</tr>
<tr>
<th class="Botrule Lrule Rrule" align="center" rowspan="2">Week</th>
<th align="center">15 mg daily</th>
<th align="center">30 mg daily</th>
<th class="Rrule" align="center">60 mg daily</th>
</tr>
<tr class="Botrule Last">
<th align="center">(N=68)</th>
<th align="center">(N=74)</th>
<th class="Rrule" align="center">(N=70)</th>
<th class="Rrule" align="center">(N=72)</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-23" href="#footnote-reference-23">*</a></dt>
<dd>(p≤0.001) versus placebo.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">2</td>
<td align="center">42.4%<a name="footnote-reference-23" href="#footnote-23" class="Sup">*</a>
</td>
<td align="center">35.6%<a href="#footnote-23" class="Sup">*</a>
</td>
<td class="Rrule" align="center">39.1%<a href="#footnote-23" class="Sup">*</a>
</td>
<td class="Rrule" align="center">11.3%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">4</td>
<td align="center">89.4%<a href="#footnote-23" class="Sup">*</a>
</td>
<td align="center">91.7%<a href="#footnote-23" class="Sup">*</a>
</td>
<td class="Rrule" align="center">89.9%<a href="#footnote-23" class="Sup">*</a>
</td>
<td class="Rrule" align="center">46.1%</td>
</tr>
</tbody>
</table>
<p>PREVACID 15 mg was significantly more effective than placebo in relieving day and nighttime <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and in decreasing the amount of antacid taken per day.</p>
<p>In a second U.S. multicenter study, also double-blind, placebo-controlled, dose-comparison (15 and 30 mg of PREVACID once daily), and including a comparison with ranitidine, in 280 patients with endoscopically documented <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>, the percentage of patients healed after four weeks was significantly higher with both doses of PREVACID than with placebo. There was no evidence of a greater or earlier response with the higher dose of PREVACID. Although the 15 mg dose of PREVACID was superior to ranitidine at 4 weeks, the lack of significant difference at 2 weeks and the absence of a difference between 30 mg of PREVACID and ranitidine leaves the comparative effectiveness of the two agents undetermined (Table 10) <span class="Italics">[see <a href="#S1.1">Indications and Usage (1.1)</a>]</span>. 								</p>
<a name="table10"></a><table width="100%">
<caption><span>Table 10: <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Healing Rates</span></caption>
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="bottom" width="20%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center"></th>
<th class="Botrule Rrule" align="center" colspan="2">PREVACID</th>
<th class="Botrule Rrule" align="center">Ranitidine</th>
<th class="Rrule" align="center" rowspan="2">Placebo</th>
</tr>
<tr>
<th class="Botrule Lrule Rrule" align="center" rowspan="2">Week</th>
<th class="Rrule" align="center">15 mg daily</th>
<th class="Rrule" align="center">30 mg daily</th>
<th class="Rrule" align="center">300 mg h.s.</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">(N=80)</th>
<th class="Rrule" align="center">(N=77)</th>
<th class="Rrule" align="center">(N=82)</th>
<th class="Rrule" align="center">(N=41)</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-24" href="#footnote-reference-24">*</a></dt>
<dd>(p≤0.05) versus placebo and ranitidine.</dd>
<dt><a name="footnote-25" href="#footnote-reference-25">†</a></dt>
<dd>(p≤0.05) versus placebo.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">35.0%</td>
<td class="Rrule" align="center">44.2%</td>
<td class="Rrule" align="center">30.5%</td>
<td class="Rrule" align="center">34.2%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">4</td>
<td class="Rrule" align="center">92.3%<a name="footnote-reference-24" href="#footnote-24" class="Sup">*</a>
</td>
<td class="Rrule" align="center">80.3%<a name="footnote-reference-25" href="#footnote-25" class="Sup">†</a>
</td>
<td class="Rrule" align="center">70.5%<a href="#footnote-25" class="Sup">†</a>
</td>
<td class="Rrule" align="center">47.5%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">H. pylori</span> Eradication to Reduce the Risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Recurrence</span></p>
<p>Randomized, double-blind clinical studies performed in the U.S. in patients with <span class="Italics">H. pylori</span> and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease (defined as an active <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or history of an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> within one year) evaluated the efficacy of PREVACID in combination with amoxicillin capsules and clarithromycin tablets as triple 14-day therapy or in combination with amoxicillin capsules as dual 14-day therapy for the eradication of <span class="Italics">H. pylori.</span> Based on the results of these studies, the safety and efficacy of two different eradication regimens were established: </p>
<a name="i52b6e39f-4977-4270-8ef9-d6d88ad5fa91"></a><table width="100%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="80%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">  Triple therapy:</td>
<td align="left">PREVACID 30 mg twice daily/amoxicillin 1 g twice daily/clarithromycin 500 mg twice daily</td>
</tr>
<tr class="Botrule Last">
<td align="left">  Dual therapy:</td>
<td align="left">PREVACID 30 mg three times daily/amoxicillin 1 g three times daily</td>
</tr>
</tbody>
</table>
<p>All treatments were for 14 days. <span class="Italics">H. pylori</span> eradication was defined as two negative tests (culture and histology) at 4 to 6 weeks following the end of treatment.</p>
<p>Triple therapy was shown to be more effective than all possible dual therapy combinations. Dual therapy was shown to be more effective than both monotherapies. Eradication of <span class="Italics">H. pylori</span> has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> recurrence.</p>
<p>A randomized, double-blind clinical study performed in the U.S. in patients with <span class="Italics">H. pylori</span> and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease (defined as an active <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or history of an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> within one year) compared the efficacy of PREVACID triple therapy for 10 and 14 days. This study established that the 10-day triple therapy was equivalent to the 14-day triple therapy in eradicating <span class="Italics">H. pylori </span>(Tables 11 and 12)<span class="Italics"> [see <a href="#S1.2">Indications and Usage (1.2)</a>]</span>. 								</p>
<a name="table11"></a><table width="100%">
<caption><span>Table 11 H. pylori Eradication Rates – Triple Therapy </span></caption>
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="First Toprule"><th class="Botrule" align="center" colspan="4">(PREVACID/amoxicillin/clarithromycin)<br>Percent of Patients Cured<br>[95% Confidence Interval]<br>(Number of patients)</th></tr>
<tr class="Last Toprule">
<th class="Lrule Rrule" align="center" valign="middle">Study</th>
<th class="Rrule" align="center" valign="middle">Duration</th>
<th class="Rrule" align="center">Triple Therapy<br>Evaluable Analysis<a name="footnote-reference-26" href="#footnote-26" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Triple Therapy<br>Intent-to-Treat Analysis<a name="footnote-reference-27" href="#footnote-27" class="Sup">†</a>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-26" href="#footnote-reference-26">*</a></dt>
<dd>Based on evaluable patients with confirmed <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> (active or within one year) and <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at baseline defined as at least two of three positive endoscopic tests from CLOtest<span class="Sup">®</span>, histology and/or culture. Patients were included in the analysis if they completed the study. Additionally, if patients dropped out of the study due to an adverse event related to the study drug, they were included in the evaluable analysis as failures of therapy.</dd>
<dt><a name="footnote-27" href="#footnote-reference-27">†</a></dt>
<dd>Patients were included in the analysis if they had documented <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at baseline as defined above and had a confirmed <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> (active or within one year). All dropouts were included as failures of therapy.</dd>
<dt><a name="footnote-28" href="#footnote-reference-28">‡</a></dt>
<dd>(p&lt;0.05) versus PREVACID/amoxicillin and PREVACID/clarithromycin dual therapy.</dd>
<dt><a name="footnote-29" href="#footnote-reference-29">§</a></dt>
<dd>(p&lt;0.05) versus clarithromycin/amoxicillin dual therapy.</dd>
<dt><a name="footnote-30" href="#footnote-reference-30">¶</a></dt>
<dd>The 95% confidence interval for the difference in eradication rates, 10-day minus 14-day is (-10.5, 8.1) in the evaluable analysis and (-9.7, 9.1) in the intent-to-treat analysis.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">M93-131</td>
<td class="Rrule" align="center">14 days</td>
<td class="Rrule" align="center">92<a name="footnote-reference-28" href="#footnote-28" class="Sup">‡</a><br>[80.0-97.7]<br>(N=48)</td>
<td class="Rrule" align="center">86<a href="#footnote-28" class="Sup">‡</a><br> [73.3-93.5]<br>(N=55)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">M95-392</td>
<td class="Rrule" align="center">14 days</td>
<td class="Rrule" align="center">86<a name="footnote-reference-29" href="#footnote-29" class="Sup">§</a><br>[75.7-93.6]<br>(N=66)</td>
<td class="Rrule" align="center">83<a href="#footnote-29" class="Sup">§</a><br>[72.0-90.8]<br>(N=70)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" rowspan="2">M95-399<a name="footnote-reference-30" href="#footnote-30" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">14 days</td>
<td class="Rrule" align="center">85<br>[77.0-91.0]<br>(N=113)</td>
<td class="Rrule" align="center">82<br>[73.9-88.1]<br>(N=126)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="center">10 days</td>
<td class="Rrule" align="center">84<br>[76.0-89.8]<br>(N=123)</td>
<td class="Rrule" align="center">81<br>[73.9-87.6]<br>(N=135)</td>
</tr>
</tbody>
</table>
<a name="table12"></a><table width="100%">
<caption><span>Table 12 H. pylori Eradication Rates – 14-Day Dual Therapy </span></caption>
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="40%">
<thead>
<tr class="First Toprule"><th class="Botrule" align="center" colspan="4">(PREVACID/amoxicillin)<br>Percent of Patients Cured<br>[95% Confidence Interval]<br>(Number of patients)</th></tr>
<tr class="Last Toprule">
<th class="Lrule Rrule" align="center">Study</th>
<th class="Rrule" align="center">Dual Therapy<br>Evaluable Analysis<a name="footnote-reference-31" href="#footnote-31" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Dual Therapy<br>Intent-to-Treat Analysis<a name="footnote-reference-32" href="#footnote-32" class="Sup">†</a>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-31" href="#footnote-reference-31">*</a></dt>
<dd>Based on evaluable patients with confirmed <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> (active or within one year) and <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at baseline defined as at least two of three positive endoscopic tests from CLOtest<span class="Sup">®</span>, histology and/or culture. Patients were included in the analysis if they completed the study. Additionally, if patients dropped out of the study due to an adverse event related to the study drug, they were included in the analysis as failures of therapy.</dd>
<dt><a name="footnote-32" href="#footnote-reference-32">†</a></dt>
<dd>Patients were included in the analysis if they had documented <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at baseline as defined above and had a confirmed <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> (active or within one year). All dropouts were included as failures of therapy.</dd>
<dt><a name="footnote-33" href="#footnote-reference-33">‡</a></dt>
<dd>(p&lt;0.05) versus PREVACID alone.</dd>
<dt><a name="footnote-34" href="#footnote-reference-34">§</a></dt>
<dd>(p&lt;0.05) versus PREVACID alone or amoxicillin alone.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">M93-131</td>
<td class="Rrule" align="center">77<a name="footnote-reference-33" href="#footnote-33" class="Sup">‡</a><br>[62.5-87.2]<br>(N=51)</td>
<td class="Rrule" align="center">70<a href="#footnote-33" class="Sup">‡</a><br>[56.8-81.2]<br>(N=60)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">M93-125</td>
<td class="Rrule" align="center">66<a name="footnote-reference-34" href="#footnote-34" class="Sup">§</a><br>[51.9-77.5]<br>(N=58)</td>
<td class="Rrule" align="center">61<a href="#footnote-34" class="Sup">§</a><br>[48.5-72.9]<br>(N=67)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.3"></a><p></p>
<p class="First"><span class="Bold">Long-Term Maintenance Treatment of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcers</span></span></p>
<p>PREVACID has been shown to prevent the recurrence of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>. Two independent, double-blind, multicenter, controlled trials were conducted in patients with endoscopically confirmed healed <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>. Patients remained healed significantly longer and the number of recurrences of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span> was significantly less in patients treated with PREVACID than in patients treated with placebo over a 12-month period (Table 13) <span class="Italics">[see <a href="#S1.3">Indications and Usage (1.3)]</a></span>. 								</p>
<a name="table13"></a><table width="100%">
<caption><span>Table 13: Endoscopic Remission Rates</span></caption>
<col align="center" valign="middle" width="10%">
<col align="left" valign="middle" width="22%">
<col align="center" valign="middle" width="17%">
<col align="center" valign="middle" width="17%">
<col align="center" valign="middle" width="17%">
<col align="center" valign="middle" width="17%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2">Trial</th>
<th class="Rrule" align="left" rowspan="2">Drug</th>
<th class="Rrule" align="center" rowspan="2">No. of Pts.</th>
<th class="Rrule" align="center" colspan="3">Percent in Endoscopic Remission</th>
</tr>
<tr class="Botrule Last">
<th class="Rrule" align="center">0-3 mo.</th>
<th class="Rrule" align="center">0-6 mo.</th>
<th class="Rrule" align="center">0-12 mo.</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="6">%=Life Table Estimate</td></tr>
<tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-35" href="#footnote-reference-35">*</a></dt>
<dd>(p≤0.001) versus placebo.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" rowspan="2">#1</td>
<td class="Rrule" align="left">PREVACID 15 mg daily</td>
<td class="Rrule" align="center">86</td>
<td class="Rrule" align="center">90%<a name="footnote-reference-35" href="#footnote-35" class="Sup">*</a>
</td>
<td class="Rrule" align="center">87%<a href="#footnote-35" class="Sup">*</a>
</td>
<td class="Rrule" align="center">84%<a href="#footnote-35" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Placebo</td>
<td class="Rrule" align="center">83</td>
<td class="Rrule" align="center">49%</td>
<td class="Rrule" align="center">41%</td>
<td class="Rrule" align="center">39%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" rowspan="3">#2</td>
<td class="Rrule" align="left">PREVACID 30 mg daily</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">94%<a href="#footnote-35" class="Sup">*</a>
</td>
<td class="Rrule" align="center">94%<a href="#footnote-35" class="Sup">*</a>
</td>
<td class="Rrule" align="center">85%<a href="#footnote-35" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">PREVACID 15 mg daily</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">87%<a href="#footnote-35" class="Sup">*</a>
</td>
<td class="Rrule" align="center">79%<a href="#footnote-35" class="Sup">*</a>
</td>
<td class="Rrule" align="center">70%<a href="#footnote-35" class="Sup">*</a>
</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">Placebo</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">33%</td>
<td class="Rrule" align="center">0%</td>
<td class="Rrule" align="center">0%</td>
</tr>
</tbody>
</table>
<p>In trial #2, no significant difference was noted between PREVACID 15 mg and 30 mg in maintaining remission.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.4"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span></span></p>
<p>In a U.S. multicenter, double-blind, placebo-controlled study of 253 patients with endoscopically documented <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>, the percentage of patients healed at four and eight weeks was significantly higher with PREVACID 15 mg and 30 mg once a day than with placebo (Table 14) <span class="Italics">[see <a href="#S1.4">Indications and Usage (1.4)</a>]</span>. 								</p>
<a name="table14"></a><table width="100%">
<caption><span>Table 14: <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span> Healing Rates</span></caption>
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="bottom" width="20%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule" align="center"></th>
<th class="Botrule Rrule" align="center" colspan="3">PREVACID</th>
<th class="Rrule" align="center" rowspan="2">Placebo</th>
</tr>
<tr>
<th class="Botrule Lrule Rrule" align="center" rowspan="2">Week</th>
<th class="Rrule" align="center">15 mg daily</th>
<th class="Rrule" align="center">30 mg daily</th>
<th class="Rrule" align="center">60 mg daily</th>
</tr>
<tr class="Botrule Last">
<th class="Rrule" align="center">(N=65)</th>
<th class="Rrule" align="center">(N=63)</th>
<th class="Rrule" align="center">(N=61)</th>
<th class="Rrule" align="center">(N=64)</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-36" href="#footnote-reference-36">*</a></dt>
<dd>(p≤0.05) versus placebo.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">4</td>
<td class="Rrule" align="center">64.6%<a name="footnote-reference-36" href="#footnote-36" class="Sup">*</a>
</td>
<td class="Rrule" align="center">58.1%<a href="#footnote-36" class="Sup">*</a>
</td>
<td class="Rrule" align="center">53.3%<a href="#footnote-36" class="Sup">*</a>
</td>
<td class="Rrule" align="center">37.5%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">8</td>
<td class="Rrule" align="center">92.2%<a href="#footnote-36" class="Sup">*</a>
</td>
<td class="Rrule" align="center">96.8%<a href="#footnote-36" class="Sup">*</a>
</td>
<td class="Rrule" align="center">93.2%<a href="#footnote-36" class="Sup">*</a>
</td>
<td class="Rrule" align="center">76.7%</td>
</tr>
</tbody>
</table>
<p>Patients treated with any PREVACID dose reported significantly less day and night <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> along with fewer days of antacid use and fewer antacid tablets used per day than the placebo group.</p>
<p>Independent substantiation of the effectiveness of PREVACID 30 mg was provided by a meta-analysis of published and unpublished data.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.5"></a><p></p>
<p class="First"><span class="Bold">Healing of NSAID-Associated <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span></span></p>
<p>In two U.S. and Canadian multicenter, double-blind, active-controlled studies in patients with endoscopically confirmed NSAID-associated <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span> who continued their NSAID use, the percentage of patients healed after 8 weeks was statistically significantly higher with 30 mg of PREVACID than with the active control. A total of 711 patients were enrolled in the study, and 701 patients were treated. Patients ranged in age from 18 to 88 years (median age 59 years), with 67% female patients and 33% male patients. Race was distributed as follows:  87% Caucasian, 8% Black, 5% Other. There was no statistically significant difference between PREVACID 30 mg daily and the active control on symptom relief (i.e., <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>) (Table 15) <span class="Italics">[see <a href="#S1.5">Indications and Usage (1.5)</a>]</span>. 								</p>
<a name="table15"></a><table width="80%">
<caption><span>Table 15: NSAID-Associated <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span> Healing Rates<a name="footnote-reference-37" href="#footnote-37" class="Sup">*</a></span></caption>
<col align="left" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="50%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-37" href="#footnote-reference-37">*</a></dt>
<dd>Actual observed <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>(s) healed at time points ± 2 days</dd>
<dt><a name="footnote-38" href="#footnote-reference-38">†</a></dt>
<dd>Dose for healing of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span></dd>
<dt><a name="footnote-39" href="#footnote-reference-39">‡</a></dt>
<dd>(p≤0.05) versus the active control</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="3">Study #1</td></tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="center">PREVACID</td>
<td class="Botrule Rrule" align="center" rowspan="2">Active Control<a name="footnote-reference-38" href="#footnote-38" class="Sup">†</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="center">30 mg daily</td>
</tr>
<tr class="Botrule">
<td class="Botrule Lrule Rrule" align="left">Week 4</td>
<td class="Botrule Rrule" align="center">60% (53/88) <a name="footnote-reference-39" href="#footnote-39" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">28% (23/83)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Week 8</td>
<td class="Rrule" align="center">79% (62/79) <a href="#footnote-39" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">55% (41/74)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule Toprule" align="center" colspan="3">Study #2</td></tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="center">PREVACID</td>
<td class="Botrule Rrule" align="center" rowspan="2">Active Control<a href="#footnote-38" class="Sup">†</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="center">30 mg daily</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Week 4</td>
<td class="Botrule Rrule" align="center">53% (40/75)</td>
<td class="Rrule" align="center">38% (31/82)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Week 8</td>
<td class="Rrule" align="center">77% (47/61) <a href="#footnote-39" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">50% (33/66)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.6"></a><p></p>
<p class="First"><span class="Bold">Risk Reduction of NSAID-Associated <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span></span></p>
<p>In one large U.S., multicenter, double-blind, placebo- and misoprostol-controlled (misoprostol blinded only to the endoscopist) study in patients who required chronic use of an NSAID and who had a history of an endoscopically documented <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>, the proportion of patients remaining free from <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span> at 4, 8, and 12 weeks was significantly higher with 15 or 30 mg of PREVACID than placebo. A total of 537 patients were enrolled in the study, and 535 patients were treated. Patients ranged in age from 23 to 89 years (median age 60 years), with 65% female patients and 35% male patients. Race was distributed as follows: 90% Caucasian, 6% Black, 4% other. The 30 mg dose of PREVACID demonstrated no additional benefit in risk reduction of the NSAID-associated <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span> than the 15 mg dose (Table 16) <span class="Italics">[see <a href="#S1.6">Indications and Usage (1.6)</a>]</span>. 								</p>
<a name="table16"></a><table width="100%">
<caption><span>Table 16: Proportion of Patients Remaining Free of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcers</span><a name="footnote-reference-40" href="#footnote-40" class="Sup">*</a></span></caption>
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="bottom" width="20%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="center">PREVACID</th>
<th class="Rrule" align="center">PREVACID</th>
<th class="Rrule" align="center">Misoprostol</th>
<th class="Rrule" align="center"></th>
</tr>
<tr>
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="center">15 mg daily</th>
<th class="Rrule" align="center">30 mg daily</th>
<th class="Rrule" align="center">200 mcg q.i.d.</th>
<th class="Rrule" align="center">Placebo</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Week</th>
<th class="Rrule" align="center">(N=121)</th>
<th class="Rrule" align="center">(N=116)</th>
<th class="Rrule" align="center">(N=106)</th>
<th class="Rrule" align="center">(N=112)</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="5">(p&lt;0.001) PREVACID 15 mg daily versus placebo; PREVACID 30 mg daily versus placebo; and misoprostol 200 mcg q.i.d. versus placebo.<br>(p&lt;0.05) Misoprostol 200 mcg q.i.d. versus PREVACID 15 mg daily; and misoprostol 200 mcg q.i.d. versus PREVACID 30 mg daily.</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-40" href="#footnote-reference-40">*</a></dt>
<dd>% = Life Table Estimate</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule Toprule" align="center">4</td>
<td class="Rrule Toprule" align="center">90%</td>
<td class="Rrule Toprule" align="center">92%</td>
<td class="Rrule Toprule" align="center">96%</td>
<td class="Rrule Toprule" align="center">66%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">8</td>
<td class="Rrule" align="center">86%</td>
<td class="Rrule" align="center">88%</td>
<td class="Rrule" align="center">95%</td>
<td class="Rrule" align="center">60%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">12</td>
<td class="Rrule" align="center">80%</td>
<td class="Rrule" align="center">82%</td>
<td class="Rrule" align="center">93%</td>
<td class="Rrule" align="center">51%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.7"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>)</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.7.1"></a><p></p>
<p class="First"><span class="Italics">Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>: </span>In a U.S. multicenter, double-blind, placebo-controlled study of 214 patients with frequent <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> symptoms, but no <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">esophageal erosions</span> by endoscopy, significantly greater relief of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> associated with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> was observed with the administration of lansoprazole 15 mg once daily up to 8 weeks than with placebo. No significant additional benefit from lansoprazole 30 mg once daily was observed.</p>
<p>The intent-to-treat analyses demonstrated significant reduction in frequency and severity of day and night <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>. Data for frequency and severity for the 8-week treatment period are presented in Table 17 and in Figures 1 and 2:</p>
<a name="table17"></a><table width="100%">
<caption><span>Table 17: Frequency of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span></span></caption>
<col align="center" valign="middle" width="28%">
<col align="center" valign="middle" width="24%">
<col align="center" valign="middle" width="24%">
<col align="center" valign="middle" width="24%">
<thead>
<tr class="First">
<th class="Lrule" align="center" rowspan="2">Variable</th>
<th class="Botrule Lrule" align="center">Placebo<br>(n=43)</th>
<th class="Botrule Lrule" align="center">PREVACID 15 mg<br>(n=80)</th>
<th class="Botrule Lrule Rrule" align="center">PREVACID 30 mg<br>(n=86)</th>
</tr>
<tr class="Last"><th class="Botrule Lrule Rrule" align="center" colspan="3">Median</th></tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-41" href="#footnote-reference-41">*</a></dt>
<dd>(p&lt;0.01) versus placebo.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="center">% of Days without <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span></td>
<td class="Botrule Lrule" align="center"></td>
<td class="Botrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">Week 1</td>
<td class="Botrule Lrule" align="center">0%</td>
<td class="Botrule Lrule" align="center">71%<a name="footnote-reference-41" href="#footnote-41" class="Sup">*</a>
</td>
<td class="Botrule Lrule Rrule" align="center">46%<a href="#footnote-41" class="Sup">*</a>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">Week 4</td>
<td class="Botrule Lrule" align="center">11%</td>
<td class="Botrule Lrule" align="center">81%<a href="#footnote-41" class="Sup">*</a>
</td>
<td class="Botrule Lrule Rrule" align="center">76%<a href="#footnote-41" class="Sup">*</a>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">Week 8</td>
<td class="Botrule Lrule" align="center">13%</td>
<td class="Botrule Lrule" align="center">84%<a href="#footnote-41" class="Sup">*</a>
</td>
<td class="Botrule Lrule Rrule" align="center">82%<a href="#footnote-41" class="Sup">*</a>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">% of Nights without <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span></td>
<td class="Botrule Lrule" align="center"></td>
<td class="Botrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">Week 1</td>
<td class="Botrule Lrule" align="center">17%</td>
<td class="Botrule Lrule" align="center">86%<a href="#footnote-41" class="Sup">*</a>
</td>
<td class="Botrule Lrule Rrule" align="center">57%<a href="#footnote-41" class="Sup">*</a>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">Week 4</td>
<td class="Botrule Lrule" align="center">25%</td>
<td class="Botrule Lrule" align="center">89%<a href="#footnote-41" class="Sup">*</a>
</td>
<td class="Botrule Lrule Rrule" align="center">73%<a href="#footnote-41" class="Sup">*</a>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center">Week 8</td>
<td class="Botrule Lrule" align="center">36%</td>
<td class="Botrule Lrule" align="center">92%<a href="#footnote-41" class="Sup">*</a>
</td>
<td class="Botrule Lrule Rrule" align="center">80%<a href="#footnote-41" class="Sup">*</a>
</td>
</tr>
</tbody>
</table>
<a name="i6732d42e-86de-454b-8f1e-579f11487939"></a><table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center">Figure 1</td></tr>
<tr class="Botrule Last"><td align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7140f8d9-e478-4f69-a4eb-3fd4c9414576&amp;name=prevacid-02.jpg"></td></tr>
</tbody>
</table>
<a name="i18b5286c-2ca0-4a8f-8c1a-23a8a05bcb26"></a><table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center">Figure 2</td></tr>
<tr class="Botrule Last"><td align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7140f8d9-e478-4f69-a4eb-3fd4c9414576&amp;name=prevacid-03.jpg"></td></tr>
</tbody>
</table>
<p>In two U.S., multicenter double-blind, ranitidine-controlled studies of 925 total patients with frequent <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> symptoms, but no <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">esophageal erosions</span> by endoscopy, lansoprazole 15 mg was superior to ranitidine 150 mg (twice daily) in decreasing the frequency and severity of day and night <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> associated with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> for the 8-week treatment period. No significant additional benefit from lansoprazole 30 mg once daily was observed <span class="Italics">[see <a href="#S1.7">Indications and Usage (1.7)</a>]</span>. 										</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.8"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></span></p>
<p>In a U.S. multicenter, double-blind, placebo-controlled study of 269 patients entering with an endoscopic diagnosis of <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> with mucosal grading of 2 or more and grades 3 and 4 signifying erosive disease, the percentages of patients with healing are presented in Table 18:</p>
<a name="i3992efd4-c23b-4947-8f8e-83ad1bcd3bd4"></a><table width="100%">
<caption><span>Table 18: <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> Healing Rates</span></caption>
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="21%">
<col align="center" valign="middle" width="21%">
<col align="center" valign="middle" width="21%">
<col align="center" valign="middle" width="21%">
<thead>
<tr class="First">
<th class="Lrule" align="center"> </th>
<th class="Botrule Lrule" align="center" colspan="3">PREVACID</th>
<th class="Lrule Rrule" align="center" valign="top"></th>
</tr>
<tr>
<th class="Lrule" align="center"></th>
<th class="Lrule" align="center">15 mg daily</th>
<th class="Lrule" align="center">30 mg daily</th>
<th class="Lrule" align="center">60 mg daily</th>
<th class="Lrule Rrule" align="center">Placebo</th>
</tr>
<tr class="Last">
<th class="Lrule" align="center">Week</th>
<th class="Lrule" align="center">(N=69)</th>
<th class="Lrule" align="center">(N=65)</th>
<th class="Lrule" align="center">(N=72)</th>
<th class="Lrule Rrule" align="center">(N=63)</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-42" href="#footnote-reference-42">*</a></dt>
<dd>(p≤0.001) versus placebo.</dd>
<dt><a name="footnote-43" href="#footnote-reference-43">†</a></dt>
<dd>(p≤0.05) versus PREVACID 15 mg.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="center">4</td>
<td class="Botrule Lrule" align="center">67.6%<a name="footnote-reference-42" href="#footnote-42" class="Sup">*</a>
</td>
<td class="Botrule Lrule" align="center">81.3% <a href="#footnote-42" class="Sup">*</a><a name="footnote-reference-43" href="#footnote-43" class="Sup">†</a>
</td>
<td class="Botrule Lrule" align="center">80.6%<a href="#footnote-42" class="Sup">*</a><a href="#footnote-43" class="Sup">†</a>
</td>
<td class="Botrule Lrule Rrule" align="center">32.8%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">6</td>
<td class="Botrule Lrule" align="center">87.7%<a href="#footnote-42" class="Sup">*</a>
</td>
<td class="Botrule Lrule" align="center">95.4%<a href="#footnote-42" class="Sup">*</a>
</td>
<td class="Botrule Lrule" align="center">94.3%<a href="#footnote-42" class="Sup">*</a>
</td>
<td class="Botrule Lrule Rrule" align="center">52.5%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center">8</td>
<td class="Botrule Lrule" align="center">90.9%<a href="#footnote-42" class="Sup">*</a>
</td>
<td class="Botrule Lrule" align="center">95.4%<a href="#footnote-42" class="Sup">*</a>
</td>
<td class="Botrule Lrule" align="center">94.4%<a href="#footnote-42" class="Sup">*</a>
</td>
<td class="Botrule Lrule Rrule" align="center">52.5%</td>
</tr>
</tbody>
</table>
<p>In this study, all PREVACID groups reported significantly greater relief of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> and less day and night <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> along with fewer days of antacid use and fewer antacid tablets taken per day than the placebo group.</p>
<p>Although all doses were effective, the earlier healing in the higher two doses suggests 30 mg daily as the recommended dose.</p>
<p>PREVACID was also compared in a U.S. multicenter, double-blind study to a low dose of ranitidine in 242 patients with erosive <span class="product-label-link" type="condition" conceptid="30437" conceptname="Gastro-esophageal reflux disease with esophagitis">reflux esophagitis</span>. PREVACID at a dose of 30 mg was significantly more effective than ranitidine 150 mg twice daily as shown below (Table 19).</p>
<a name="i6777b815-1a08-4b10-8d41-5cf779fac94f"></a><table width="80%">
<caption><span>Table 19: <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> Healing Rates</span></caption>
<col align="center" valign="bottom" width="24%">
<col align="center" valign="middle" width="38%">
<col align="center" valign="middle" width="38%">
<thead><tr class="First Last">
<th class="Botrule Lrule" align="center">Week</th>
<th class="Botrule Lrule" align="center">PREVACID<br>30 mg daily<br>(N=115)</th>
<th class="Botrule Lrule Rrule" align="center">Ranitidine<br>150 mg twice daily<br>(N=127)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-44" href="#footnote-reference-44">*</a></dt>
<dd>(p≤0.001) versus ranitidine.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="center">2</td>
<td class="Botrule Lrule" align="center">66.7%<a name="footnote-reference-44" href="#footnote-44" class="Sup">*</a>
</td>
<td class="Botrule Lrule Rrule" align="center">38.7%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">4</td>
<td class="Botrule Lrule" align="center">82.5%<a href="#footnote-44" class="Sup">*</a>
</td>
<td class="Botrule Lrule Rrule" align="center">52.0%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">6</td>
<td class="Botrule Lrule" align="center">93.0%<a href="#footnote-44" class="Sup">*</a>
</td>
<td class="Botrule Lrule Rrule" align="center">67.8%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center">8</td>
<td class="Botrule Lrule" align="center">92.1%<a href="#footnote-44" class="Sup">*</a>
</td>
<td class="Botrule Lrule Rrule" align="center">69.9%</td>
</tr>
</tbody>
</table>
<p>In addition, patients treated with PREVACID reported less day and nighttime <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> and took less antacid tablets for fewer days than patients taking ranitidine 150 mg twice daily.</p>
<p>Although this study demonstrates effectiveness of PREVACID in healing <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>, it does not represent an adequate comparison with ranitidine because the recommended ranitidine dose for <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> is 150 mg q.i.d., twice the dose used in this study.</p>
<p>In the two trials described and in several smaller studies involving patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>, PREVACID produced healing rates similar to those shown above.</p>
<p>In a U.S. multicenter, double-blind, active-controlled study, 30 mg of PREVACID was compared with ranitidine 150 mg twice daily in 151 patients with erosive <span class="product-label-link" type="condition" conceptid="30437" conceptname="Gastro-esophageal reflux disease with esophagitis">reflux esophagitis</span> that was poorly responsive to a minimum of 12 weeks of treatment with at least one H<span class="Sub">2</span>-receptor antagonist given at the dose indicated for symptom relief or greater, namely, cimetidine 800 mg/day, ranitidine 300 mg/day, famotidine 40 mg/day or nizatidine 300 mg/day. </p>
<p>PREVACID 30 mg was more effective than ranitidine 150 mg twice daily in healing <span class="product-label-link" type="condition" conceptid="30437" conceptname="Gastro-esophageal reflux disease with esophagitis">reflux esophagitis</span>, and the percentage of patients with healing were as follows. This study does not constitute a comparison of the effectiveness of histamine H<span class="Sub">2</span>-receptor antagonists with PREVACID, as all patients had demonstrated unresponsiveness to the histamine H<span class="Sub">2</span>-receptor antagonist mode of treatment. It does indicate, however, that PREVACID may be useful in patients failing on a histamine H<span class="Sub">2</span>-receptor antagonist (Table 20) <span class="Italics">[see <a href="#S1.7">Indications and Usage (1.7)</a>]</span>.</p>
<a name="i927c7d7c-8f22-429c-8da0-cc74c7e68422"></a><table width="75%">
<caption><span>Table 20: <span class="product-label-link" type="condition" conceptid="30437" conceptname="Gastro-esophageal reflux disease with esophagitis">Reflux Esophagitis</span> Healing Rates in Patients Poorly Responsive to Histamine H<span class="Sub">2</span>-Receptor Antagonist Therapy</span></caption>
<col align="center" valign="middle" width="24%">
<col align="center" valign="middle" width="38%">
<col align="center" valign="middle" width="38%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Week</th>
<th class="Lrule" align="center">PREVACID<br>30 mg daily<br>(N=100)</th>
<th class="Lrule Rrule" align="center">Ranitidine<br>150 mg twice daily<br>(N=51)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-45" href="#footnote-reference-45">*</a></dt>
<dd>(p≤0.001) versus ranitidine.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center">4</td>
<td class="Lrule" align="center">74.7%<a name="footnote-reference-45" href="#footnote-45" class="Sup">*</a>
</td>
<td class="Lrule Rrule" align="center">42.6%</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">8</td>
<td class="Lrule" align="center">83.7%<a href="#footnote-45" class="Sup">*</a>
</td>
<td class="Lrule Rrule" align="center">32.0%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.9"></a><p></p>
<p class="First"><span class="Bold">Long-Term Maintenance Treatment of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></span></p>
<p>Two independent, double-blind, multicenter, controlled trials were conducted in patients with endoscopically confirmed healed <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>. Patients remained in remission significantly longer and the number of recurrences of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> was significantly less in patients treated with PREVACID than in patients treated with placebo over a 12-month period (Table 21).</p>
<a name="i343a6e5d-47ae-418a-8a2f-8f8dedd73d1d"></a><table width="100%">
<caption><span>Table 21: Endoscopic Remission Rates</span></caption>
<col align="center" valign="top" width="8%">
<col align="left" valign="top" width="26%">
<col align="center" valign="top" width="16.5%">
<col align="center" valign="top" width="16.5%">
<col align="center" valign="top" width="16.5%">
<col align="center" valign="top" width="16.5%">
<thead>
<tr class="First">
<th class="Botrule Lrule" align="center"></th>
<th class="Botrule Lrule" align="left" colspan="2"></th>
<th class="Botrule Lrule Rrule" align="center" colspan="3">												Percent in Endoscopic Remission</th>
</tr>
<tr class="Last">
<th class="Lrule" align="center">Trial</th>
<th class="Lrule" align="left">Drug</th>
<th class="Lrule" align="center">No. of Pts.</th>
<th class="Lrule" align="center">0-3 mo.</th>
<th class="Lrule" align="center">0-6 mo.</th>
<th class="Lrule Rrule" align="center">0-12 mo.</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="6">%=Life Table Estimate</td></tr>
<tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-46" href="#footnote-reference-46">*</a></dt>
<dd>(p≤0.001) versus placebo.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center" rowspan="3">#1</td>
<td class="Lrule" align="left">PREVACID 15 mg daily</td>
<td class="Lrule" align="center">59</td>
<td class="Lrule" align="center">83%<a name="footnote-reference-46" href="#footnote-46" class="Sup">*</a>
</td>
<td class="Lrule" align="center">81%<a href="#footnote-46" class="Sup">*</a>
</td>
<td class="Lrule Rrule" align="center">79%<a href="#footnote-46" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">PREVACID 30 mg daily</td>
<td class="Lrule" align="center">56</td>
<td class="Lrule" align="center">93%<a href="#footnote-46" class="Sup">*</a>
</td>
<td class="Lrule" align="center">93%<a href="#footnote-46" class="Sup">*</a>
</td>
<td class="Lrule Rrule" align="center">90%<a href="#footnote-46" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Placebo</td>
<td class="Lrule" align="center">55</td>
<td class="Lrule" align="center">31%</td>
<td class="Lrule" align="center">27%</td>
<td class="Lrule Rrule" align="center">24%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center" rowspan="3">#2</td>
<td class="Lrule" align="left">PREVACID 15 mg daily</td>
<td class="Lrule" align="center">50</td>
<td class="Lrule" align="center">74%<a href="#footnote-46" class="Sup">*</a>
</td>
<td class="Lrule" align="center">72%<a href="#footnote-46" class="Sup">*</a>
</td>
<td class="Lrule Rrule" align="center">67%<a href="#footnote-46" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">PREVACID 30 mg daily</td>
<td class="Lrule" align="center">49</td>
<td class="Lrule" align="center">75%<a href="#footnote-46" class="Sup">*</a>
</td>
<td class="Lrule" align="center">72%<a href="#footnote-46" class="Sup">*</a>
</td>
<td class="Lrule Rrule" align="center">55%<a href="#footnote-46" class="Sup">*</a>
</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">Placebo</td>
<td class="Lrule" align="center">47</td>
<td class="Lrule" align="center">16%</td>
<td class="Lrule" align="center">13%</td>
<td class="Lrule Rrule" align="center">13%</td>
</tr>
</tbody>
</table>
<p>Regardless of initial grade of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>, PREVACID 15 mg and 30 mg were similar in maintaining remission.</p>
<p>In a U.S., randomized, double-blind, study, PREVACID 15 mg daily (n = 100) was compared with ranitidine 150 mg twice daily (n = 106), at the recommended dosage, in patients with endoscopically-proven healed <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> over a 12-month period. Treatment with PREVACID resulted in patients remaining healed (Grade 0 lesions) of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> for significantly longer periods of time than those treated with ranitidine (p&lt;0.001). In addition, PREVACID was significantly more effective than ranitidine in providing complete relief of both daytime and nighttime <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>. Patients treated with PREVACID remained asymptomatic for a significantly longer period of time than patients treated with ranitidine <span class="Italics">[see <a href="#S1.8">Indications and Usage (1.8)</a>]</span>. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.10"></a><p></p>
<p class="First"><span class="Bold">Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome</span></p>
<p>In open studies of 57 patients with pathological hypersecretory conditions, such as Zollinger-Ellison syndrome (ZES) with or without multiple endocrine <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span>, PREVACID significantly inhibited gastric acid secretion and controlled associated symptoms of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Doses ranging from 15 mg every other day to 180 mg per day maintained basal acid secretion below 10 mEq/hr in patients without prior gastric surgery and below 5 mEq/hr in patients with prior gastric surgery. </p>
<p>Initial doses were titrated to the individual patient need, and adjustments were necessary with time in some patients <span class="Italics">[see <a href="#S2.1">Dosage and Administration (2.1)</a>]. </span>PREVACID was well tolerated at these high dose levels for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> (greater than four years in some patients). In most ZES patients, serum gastrin levels were not modified by PREVACID. However, in some patients, serum gastrin increased to levels greater than those present prior to initiation of lansoprazole therapy <span class="Italics">[see <a href="#S1.9">Indications and Usage (1.9)</a>]</span>. 								</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="S15"></a><a name="section-14"></a><p></p>
<h1>15	REFERENCES</h1>
<ol><li>National Committee for Clinical Laboratory Standards. Summary Minutes, Subcommittee on Antimicrobial Susceptibility Testing, Tampa, FL, January 11-13, 1998.</li></ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-15"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">PREVACID Delayed-Release Capsules, 15 mg, are opaque, hard gelatin, colored pink and green with "TAP" and "PREVACID 15" imprinted on the capsules. The 30 mg capsules are opaque, hard gelatin, colored pink and black with "TAP" and "PREVACID 30" imprinted on the capsules. They are available as follows:</p>
<a name="iac837f28-6247-406d-8224-40e98cf0846e"></a><table width="40%"><tbody class="Headless">
<tr class="First">
<td>15 mg Capsules<br>
</td>
<td><br></td>
</tr>
<tr>
<td>NDC 54868-3867-0<br>
</td>
<td>Bottles of 30<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>30 mg Capsules<br>
</td>
<td><br></td>
</tr>
<tr>
<td>NDC 54868-4079-1<br>
</td>
<td>Bottles of 10<br>
</td>
</tr>
<tr>
<td>NDC 54868-4079-0<br>
</td>
<td>Bottles of 30<br>
</td>
</tr>
<tr>
<td>NDC 54868-4079-2<br>
</td>
<td>Bottles of 60<br>
</td>
</tr>
<tr>
<td>NDC 54868-4079-5<br>
</td>
<td>Bottles of 90<br>
</td>
</tr>
<tr>
<td>NDC 54868-4079-3<br>
</td>
<td>Bottles of 100<br>
</td>
</tr>
<tr class="Last">
<td>NDC 54868-4079-4<br>
</td>
<td>Bottles of 1000<br>
</td>
</tr>
</tbody></table>PREVACID SoluTab Delayed-Release Orally Disintegrating Tablets, 15 mg, are white to yellowish white uncoated tablets with orange to dark brown speckles, with "15" debossed on one side of the tablet. The 30 mg are white to yellowish white uncoated tablets with orange to dark brown speckles, with "30" debossed on one side of the tablet. The tablets are available as follows:<br><a name="i84aaca0b-528c-4264-8cc5-5ff13f5bf7dc"></a><table width="40%"><tbody class="Headless">
<tr class="First">
<td>15 mg SoluTab Tablets<br>
</td>
<td><br></td>
</tr>
<tr>
<td>NDC 54868-5795-0<br>
</td>
<td>Bottles of 30<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>30 mg SoluTab Tablets<br>
</td>
<td><br></td>
</tr>
<tr>
<td>NDC 54868-5303-1<br>
</td>
<td>Bottles of 10<br>
</td>
</tr>
<tr class="Last">
<td>NDC 54868-5303-0<br>
</td>
<td>Bottles of 30<br>
</td>
</tr>
</tbody></table>
<br><br><div class="Section" data-sectionCode="44425-7">
<a name="section-15.1"></a><p></p>
<p class="First">Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F)[see USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-16"></a><p></p>
<h1>17	PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patient should be informed of the following:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<h2>17.1	Information for Patients</h2>
<p class="First">PREVACID is available as a capsule andan orally disintegrating tablet, and is available in 15 mg and 30 mg strengths. Directions for use specific to the route and available methods of administration for each of these dosage forms is presented below <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a>]</span>. 								</p>
<ul>
<li>PREVACID should be taken before eating.</li>
<li>PREVACID products SHOULD NOT BE CRUSHED OR CHEWED.</li>
<li><span class="Bold">Phenylketonurics: Contains Phenylalanine 2.5 mg per 15 mg Tablet and 5.1 mg per 30 mg Tablet.</span></li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1.1"></a><p></p>
<p class="First"><span class="Italics">Administration Options</span></p>
<dl>
<dt class="Italics">1</dt>
<dd>
<span class="Italics">PREVACID Delayed-Release Capsules - Oral Administration</span><ul class="Disc">
<li>PREVACID Delayed-Release Capsules should be swallowed whole.</li>
<li>Alternatively, for patients who have difficulty swallowing capsules, PREVACID Delayed-Release Capsules can be opened and administered as follows: 									<ul class="Circle">
<li>Open capsule.</li>
<li>Sprinkle intact granules on one tablespoon of either applesauce, ENSURE<span class="Sup">®</span> pudding, cottage cheese, yogurt or strained pears.</li>
<li>Swallow immediately.</li>
</ul>
</li>
<li>PREVACID Delayed-Release Capsules may also be emptied into a small volume of either apple juice, orange juice or tomato juice and administered as follows: 									<ul class="Circle">
<li>Open capsule.</li>
<li>Sprinkle intact granules into a small volume of either apple juice, orange juice or tomato juice (60 mL – approximately 2 ounces). </li>
<li>Mix briefly.</li>
<li>Swallow immediately.</li>
<li>To ensure complete delivery of the dose, the glass should be rinsed with two or more volumes of juice and the contents swallowed immediately.</li>
</ul>
</li>
</ul>
</dd>
</dl>
<dl>
<dt> </dt>
<dd>
<span class="Italics">PREVACID Delayed-Release Capsules - Nasogastric Tube  (≥16 French) Administration</span><ul class="Disc"><li>For patients who have a nasogastric tube in place, PREVACID Delayed-Release Capsules can be administered as follows: 												<ul class="Circle">
<li>Open capsule.</li>
<li>Mix intact granules into 40 mL of apple juice. DO NOT USE OTHER LIQUIDS.</li>
<li>Inject through the nasogastric tube into the stomach. </li>
<li>Flush with additional apple juice to clear the tube. </li>
</ul>
</li></ul>
</dd>
</dl>
<p>USE IN OTHER FOODS AND LIQUIDS HAS NOT BEEN STUDIED CLINICALLY AND IS THEREFORE NOT RECOMMENDED.</p>
<dl>
<dt class="Italics">2</dt>
<dd>
<span class="Italics">PREVACID SoluTab Delayed-Release Orally Disintegrating Tablets</span><ul>
<li>PREVACID SoluTab should not be broken or cut.</li>
<li>PREVACID SoluTab should not be chewed. 									<ul class="Circle">
<li>Place the tablet on the tongue and allow it to disintegrate, with or without water, until the particles can be swallowed.</li>
<li>The tablet typically disintegrates in less than 1 minute.</li>
<li>Alternatively, for children or other patients who have difficulty swallowing tablets, PREVACID SoluTab can be delivered in two different ways.<br><span class="Italics">PREVACID SoluTab – Oral Syringe</span><br>For administration via oral syringe, PREVACID SoluTab can be administered as follows:  																	<ul class="Square">
<li>Place a 15 mg tablet in oral syringe and draw up approximately 4 mL of water, or place a 30 mg tablet in oral syringe and draw up approximately 10 mL of water.</li>
<li>Shake gently to allow for a quick dispersal.</li>
<li>After the tablet has dispersed, administer the contents within 15 minutes.</li>
<li>Refill the syringe with approximately 2 mL (5 mL for the 30 mg tablet) of water, shake gently, and administer any remaining contents.</li>
</ul>
<span class="Italics">PREVACID SoluTab – Nasogastric Tube (≥ 8 French) Administration</span><br>For administration via a nasogastric tube, PREVACID SoluTab can be administered as follows: <ul class="Square">
<li>Place a 15 mg tablet in a syringe and draw up 4 mL of water, or place a 30 mg tablet in a syringe and draw up 10 mL of water.</li>
<li>Shake gently to allow for a quick dispersal.</li>
<li>After the tablet has dispersed, inject through the nasogastric tube into the stomach within 15 minutes.</li>
<li>Refill the syringe with approximately 5 mL of water, shake gently, and flush the nasogastric tube.</li>
</ul>
</li>
</ul>
</li>
</ul>
</dd>
</dl>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
<p class="First">Distributed by<br><span class="Bold">Takeda Pharmaceuticals America, Inc.</span><br>Deerfield, IL 60015</p>
<p>PREVACID<span class="Sup">®</span> is a registered trademark and SoluTab<span class="Sup">TM </span>is a trademark of Takeda Pharmaceuticals North America, Inc. and used under license by Takeda Pharmaceuticals America, Inc.</p>
<p>All other trademark names are the property of their respective owners.</p>
<p>U.S. Patent Nos. - 4,628,098; 5,013,743; 5,464,632; and 6,328,994</p>
<p>© 1995-2009 Takeda Pharmaceuticals America, Inc.</p>
<p>PRV0909 R34; October 2009</p>
<br><p><br></p>
<p>Relabeling and Repackaging by:</p>
<p><span class="Bold">Physicians Total Care, Inc.</span><br>Tulsa, OK       74146<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 15 mg Capsules     <br></span></p>
<p><span>PREVACID</span><span class="Sup">®</span><br>LANSOPRAZOLE<br>DELAYED-RELEASE CAPSULES</p>
<p><span class="Bold">15 mg</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 15 mg Capsules" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7140f8d9-e478-4f69-a4eb-3fd4c9414576&amp;name=15mg%20Capsule%20package%20label.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 30 mg Capsules Bottle of 1000</span></p>
<p><span>PREVACID</span><span class="Sup">®</span><br>LANSOPRAZOLE<br>DELAYED-RELEASE CAPSULES</p>
<p><span class="Bold">30 mg</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 30 mg Capsules" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7140f8d9-e478-4f69-a4eb-3fd4c9414576&amp;name=30mg%20Capsule%20package%20label.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 15 mg SoluTab <br></span></p>
<p><span>PREVACID</span><span class="Sup">® </span><span>SoluTab</span><span class="Bold">™</span><br><span>LANSOPRAZOLE<br>Delayed-Release Orally Disintegrating Tablets</span></p>
<p><span class="Bold">15 mg</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 15 mg SoluTab" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7140f8d9-e478-4f69-a4eb-3fd4c9414576&amp;name=15mg%20Tablet%20package%20label.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-21"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 30 mg SoluTab <br></span></p>
<p><span>PREVACID</span><span class="Sup">® </span><span>SoluTab</span><span class="Bold">™</span><br><span>LANSOPRAZOLE<br>Delayed-Release Orally Disintegrating Tablets</span></p>
<p><span class="Bold">30 mg</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 30 mg SoluTab" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7140f8d9-e478-4f69-a4eb-3fd4c9414576&amp;name=30mg%20Tablet%20package%20label.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PREVACID 		
					</strong><br><span class="contentTableReg">lansoprazole capsule, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-3867(NDC:64764-541)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LANSOPRAZOLE</strong> (LANSOPRAZOLE) </td>
<td class="formItem">LANSOPRAZOLE</td>
<td class="formItem">15 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C RED NO. 28</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C GREEN NO. 3</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">green (Opaque, hard gelatin colored pink and green) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (Capsule) </td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TAP;PREVACID;15</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-3867-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020406</td>
<td class="formItem">11/28/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PREVACID 		
					</strong><br><span class="contentTableReg">lansoprazole capsule, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4079(NDC:64764-046)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LANSOPRAZOLE</strong> (LANSOPRAZOLE) </td>
<td class="formItem">LANSOPRAZOLE</td>
<td class="formItem">30 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>methacrylic acid - ethyl acrylate copolymer (1:1) type A</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C RED NO. 28</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">pink (Opaque, hard gelatin colored pink and black) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (Capsule) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TAP;PREVACID;30</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4079-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-4079-1</td>
<td class="formItem">10  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-4079-2</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:54868-4079-3</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:54868-4079-4</td>
<td class="formItem">1000  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem">NDC:54868-4079-5</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020406</td>
<td class="formItem">08/30/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PREVACID 		
					</strong><br><span class="contentTableReg">lansoprazole tablet, orally disintegrating, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5795(NDC:64764-543)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LANSOPRAZOLE</strong> (LANSOPRAZOLE) </td>
<td class="formItem">LANSOPRAZOLE</td>
<td class="formItem">15 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHACRYLIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ASPARTAME</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERYL MONOSTEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PHENYLALANINE</strong></td>
<td class="formItem">2.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white to yellowish white uncoated tablets with orange to dark brown speckles) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (Tablet) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">STRAWBERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">15</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5795-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021428</td>
<td class="formItem">07/11/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PREVACID 		
					</strong><br><span class="contentTableReg">lansoprazole tablet, orally disintegrating, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5303(NDC:64764-544)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LANSOPRAZOLE</strong> (LANSOPRAZOLE) </td>
<td class="formItem">LANSOPRAZOLE</td>
<td class="formItem">30 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHACRYLIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ASPARTAME</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERYL MONOSTEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PHENYLALANINE</strong></td>
<td class="formItem">5.1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white to yellowish white uncoated tablets with orange to dark brown speckles) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (Tablet) </td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">STRAWBERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">30</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5303-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5303-1</td>
<td class="formItem">10  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021428</td>
<td class="formItem">05/17/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">RELABEL, REPACK</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>183fd856-868e-459a-8361-66ca5ac363e3</div>
<div>Set id: 7140f8d9-e478-4f69-a4eb-3fd4c9414576</div>
<div>Version: 2</div>
<div>Effective Time: 20091030</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
